var title_f19_61_20432="Large CBD stones ERCP";
var content_f19_61_20432=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67099%7EGAST%2F70088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67099%7EGAST%2F70088&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Common bile duct stones",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 265px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic retrograde cholangiopancreatographic study in a patient with obstructive jaundice shows multiple stones (arrows) in a dilated common bile duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Obstructing stone in common bile duct",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 225px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Following cannulation of the distal common bile duct during an endoscopic retrograde cholangiopancreatography examination (black arrow indicates cannula), contrast material was injected, outlining a large stone producing complete obstruction of the distal duct (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_61_20432=[""].join("\n");
var outline_f19_61_20432=null;
var title_f19_61_20433="Resectoscope assembly 2";
var content_f19_61_20433=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62804&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hysteroscopy: Resectoscope assembly 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Linda D Bradley, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_61_20433=[""].join("\n");
var outline_f19_61_20433=null;
var title_f19_61_20434="Paramet boost stgIIB cc";
var content_f19_61_20434=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57654&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 607px\">",
"   <div class=\"ttl\">",
"    Parametrial boost for cervical cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 587px; height: 197px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Treatment fields for a parametrial boost for a stage IIB cervical cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kristin Bradley, MD and Derek McHaffie, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_61_20434=[""].join("\n");
var outline_f19_61_20434=null;
var title_f19_61_20435="Benzyl alcohol: Drug information";
var content_f19_61_20435=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Benzyl alcohol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/50/23332?source=see_link\">",
"    see \"Benzyl alcohol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/10/12451?source=see_link\">",
"    see \"Benzyl alcohol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7897463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ulesfia&reg;;",
"     </li>",
"     <li>",
"      Zilactin&reg;-L [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7695207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Topical;",
"     </li>",
"     <li>",
"      Antiparasitic Agent, Topical;",
"     </li>",
"     <li>",
"      Pediculocide;",
"     </li>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7897495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cold sores/fever blisters:",
"     </b>",
"     Topical liquid:: Apply to affected area up to 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Head lice:",
"     </b>",
"     Topical lotion: Apply appropriate volume for hair length to dry hair and completely saturate the scalp; leave on for 10 minutes; rinse thoroughly with water; repeat in 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hair length 0-2 inches: 4-6 ounces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hair length 2-4 inches: 6-8 ounces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hair length 4-8 inches: 8-12 ounces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hair length 8-16 inches: 12-24 ounces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hair length 16-22 inches: 24-32 ounces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hair length &gt;22 inches: 32-48 ounces",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7897494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/10/12451?source=see_link\">",
"      see \"Benzyl alcohol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Cold sores:",
"     </b>",
"     Topical liquid: Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Head lice:",
"     </b>",
"     Topical lotion: Children &ge;6 months: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7897496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7897529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zilactin&reg;-L: 10% (5.9 mL) [contains ethanol 80%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ulesfia&reg;: 5% (227 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7897643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7897525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For topical use only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid: Apply to affected area only with moistened cotton swab. Allow to dry 15 seconds. Alcohol-based topical products are flammable; keep away from fire or flame until liquid has dried.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lotion: Apply to dry hair until completely saturated. Leave on for 10 minutes, followed by a thorough water rinse. Avoid contact with eyes. Wash hands after application.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7695209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Liquid (Zilactin&reg;-L): Temporary relief of pain from cold sores/fever blisters",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lotion (Ulesfia&trade;): Treatment of head lice infestation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7695205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Benzyl alcohol may be confused with benzoyl peroxide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7897484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Dermatologic: Pruritus (12%), erythema (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Anesthesia (2%), hypoesthesia (2%), irritation (2%), pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Ocular irritation (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Dandruff, dermatitis, dryness, excoriation, exfoliation, paresthesia, rash, thermal burn",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7897469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the FDA-approved manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7897470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Contact dermatitis: Allergic or irritant dermatitis may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Eye irritation: Avoid eye exposure. If eye is exposed, flush immediately with water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Children: Use under direct adult supervision. Keep out of children&rsquo;s reach. Lotion not recommended for children &lt;6 months due to the potential for increased absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Safety of lotion not established in patients &gt;60 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neonates: Intravenous administration of benzyl alcohol-containing products has been associated with a neonatal gasping syndrome. Patients &lt;1 month of age or premature neonates with a corrected gestational age &lt;44 weeks could be at risk if treated with topical benzyl alcohol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Self-medication (OTC use): Discontinue use and notify healthcare provider if condition worsens or does not improve within 7 days, or if swelling, rash, or fever develops. Do not use for &gt;7 days unless instructed by healthcare professional.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7899266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7897464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7897465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no well-controlled human studies with topical benzyl alcohol in pregnancy. Use only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7897467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7897468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is unknown if benzyl alcohol is distributed in human milk. Use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7897523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits respiration of lice by obstructing respiratory spiracles causing lice asphyxiation. No ovicidal activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7897490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Lotion: Following a prolonged application (30 minutes), serum concentrations were detectable (&le;3 mcg/mL) at 30 and 60 minutes postexposure in patients 6 months to 11 years of age.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Frankowski BL and Bocchini JA Jr, &ldquo;Head Lice,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2010, 126(2):392-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/61/20435/abstract-text/20660553/pubmed\" id=\"20660553\" target=\"_blank\">",
"        20660553",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9067 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-71122602D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_61_20435=[""].join("\n");
var outline_f19_61_20435=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897463\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7695207\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897495\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897494\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897496\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897529\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897643\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897525\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7695209\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7695205\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897484\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897469\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897470\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298848\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7899266\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897464\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897465\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897467\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897468\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897523\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7897490\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9067\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9067|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/50/23332?source=related_link\">",
"      Benzyl alcohol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/10/12451?source=related_link\">",
"      Benzyl alcohol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_61_20436="Epoprostenol: Patient drug information";
var content_f19_61_20436=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Epoprostenol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=see_link\">",
"     see \"Epoprostenol: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/63/22519?source=see_link\">",
"     see \"Epoprostenol: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F165855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flolan&reg;;",
"     </li>",
"     <li>",
"      Veletri&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F165856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Flolan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691894",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high pressure in the lungs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702033",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to epoprostenol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing. Wearing layers of clothes or summer clothes and staying in cool places may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698194",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Jaw pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698084",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into the vein nonstop.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696361",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store as you have been told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11532 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-221.179.173.170-312020EB49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_61_20436=[""].join("\n");
var outline_f19_61_20436=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165855\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F165856\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014304\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014303\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014308\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014309\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014311\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014306\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014307\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014312\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014313\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/22/359?source=related_link\">",
"      Epoprostenol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/63/22519?source=related_link\">",
"      Epoprostenol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_61_20437="Strong ions and the analysis of acid-base disturbances (Stewart approach)";
var content_f19_61_20437=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Strong ions and the analysis of acid-base disturbances (Stewart approach)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/61/20437/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/61/20437/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/61/20437/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/61/20437/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/61/20437/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/61/20437/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/61/20437/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most internists use an approach to acid-base disturbances that was popularized by Relman and Schwartz in the 1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This \"traditional\" approach accepts the Br&oslash;nsted-Lowry definitions of acids and bases. The hydrogen ion concentration is expressed in blood as a function of the ratio between the PCO2 and the serum bicarbonate concentration as defined by the following equation:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; [H+] &nbsp;= &nbsp;K &nbsp;x &nbsp;",
"    <span class=\"nowrap\">",
"     PCO2/[HCO3-]",
"    </span>",
"   </p>",
"   <p>",
"    where K is the dissociation constant for the reaction and PCO2 is equal to the partial pressure of carbon dioxide.",
"   </p>",
"   <p>",
"    An analysis of metabolic acidosis using the traditional approach is presented in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link\">",
"     \"Approach to the adult with metabolic acidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, many surgeons, critical care specialists, and anesthesiologists have embraced an approach introduced by Peter Stewart in 1981 [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. This alternative approach, termed strong ion difference (SID) or the Stewart approach, will be reviewed briefly in this topic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRONG ION DIFFERENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardinal tenet of the Stewart approach is that the serum bicarbonate concentration does not alter blood pH. Stewart defined acids as ions that shift the dissociation equilibrium of water to a higher concentration of H+ and a lower concentration of OH-. This is in contrast to the Br&oslash;nsted-Lowry approach, which defines acids as proton donors and bases as proton acceptors.",
"   </p>",
"   <p>",
"    The Stewart approach is based upon mathematics and simple physicochemical principles. Stewart identified six simultaneous equations that define the hydrogen ion concentration in terms of its dissociation equilibrium with various constituents present in plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/8\">",
"     8",
"    </a>",
"    ]. A polynomial solution for the six simultaneous equations solved for the hydrogen ion concentration led to the conclusion that the serum bicarbonate is a dependent and not an independent variable. As a result, the serum bicarbonate concentration is",
"    <strong>",
"     not",
"    </strong>",
"    a determinant of blood pH.",
"   </p>",
"   <p>",
"    According to this theory as modified by Figge and Watson, the independent variables responsible for changes in acid-base balance are [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The \"strong ion difference\" or \"SID\", the difference between the completely dissociated cations and anions in plasma. Because not all strong ions can be measured, the \"apparent SID\" or \"SIDapp\" is calculated from the net charge of the major strong cations: Na+, K+, Ca++, Mg++, and the major strong anions: Cl- and lactate.",
"     </li>",
"     <li>",
"      The plasma concentration of nonvolatile weak acids (ATot). As opposed to strong ions, weak acids can exist at physiologic pH as dissociated (A-) or associated with a proton (AH). ATot = A- + AH. Weak acids are often referred to as buffers. In health, ATot is comprised primarily of phosphate and the ion equivalence of the albumin concentration; in the absence of unmeasured ions, A- is equal to the anion gap (see below).",
"     </li>",
"     <li>",
"      The arterial carbon dioxide tension (PaCO2)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because clinically important acid-base derangements are thought to result from changes in PaCO2, SID, and ATot, the strong ion approach distinguishes six primary acid-base disturbances. These are respiratory acidosis, respiratory alkalosis, strong ion acidosis, strong ion alkalosis, nonvolatile buffer ion acidosis, and nonvolatile buffer ion alkalosis. The traditional approach to these issues is discussed separately in the appropriate topic reviews on metabolic and respiratory acidosis and alkalosis.",
"   </p>",
"   <p>",
"    Clinically, the \"apparent SID\" (SIDapp) is defined as the difference between the sum of the strong cations (Na+, K+, Ca++, Mg++) and the sum of the net charge of major strong anions present in health (Cl- and lactate):",
"   </p>",
"   <p>",
"    SIDapp = [Na+] + [K+] + [Ca++] + [Mg++] - [Cl-] - [lactate-]",
"   </p>",
"   <p>",
"    Under normal conditions, the SIDapp is approximately 40",
"    <span class=\"nowrap\">",
"     mEq/L;",
"    </span>",
"    processes that increase the strong ion difference increase blood pH, whereas processes that reduce it decrease pH. As an example, the loss of gastric fluid, which has a higher concentration of chloride than cation, increases the SIDapp, causing alkalosis; by comparison, infusion of sodium chloride, a solution with a SID of zero, reduces the SIDapp, and is therefore acidifying. The Stewart approach attributes gastric alkalosis to excessive loss of chloride (and its effect on SID) rather than to loss of hydrogen ion and it attributes acidosis caused by large volume saline infusions to the excessive gain of chloride rather than to dilution of the serum bicarbonate concentration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Strong ion gap",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since SID is a function of pH and ATot, it can be calculated from measured values of pH, serum albumin, and phosphate. The calculated value, called the \"effective strong ion difference\" or \"SIDeff,\" is expressed in Figure 1 (",
"    <a class=\"graphic graphic_table graphicRef59352 \" href=\"UTD.htm?0/58/939\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    The difference between SIDapp and SIDeff is the \"strong ion gap\" or SIG:",
"   </p>",
"   <p>",
"    &nbsp;SIG &nbsp;= &nbsp;SIDapp &nbsp;- &nbsp;SIDeff",
"   </p>",
"   <p>",
"    The strong ion gap should be zero. A positive value suggests a possible organic acidosis due to endogenous acids or the intake of exogenous acids or acid precursors (e.g. methanol, ethylene glycol, or salicylates) .",
"   </p>",
"   <p>",
"    Given the complexity of these equations, preprogrammed calculators are available that permit clinicians to enter the variables that determine the strong ion gap. A print out subsequently defines the acid-base disturbance in terms of the Stewart approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     STRONG ION VERSUS TRADITIONAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Stewart or strong ion approach to acid-base disturbances has gained acceptance among many intensivists because of perceived weaknesses of the traditional approach in the evaluation of patients with critical illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The major practical difference between the two approaches is the inclusion of the serum albumin concentration in the Stewart approach, which provides some increase in accuracy in certain clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, if serum albumin concentration is considered in the traditional analysis of acid-base disturbances, we feel that the Stewart approach offers no advantage over the traditional Schwartz-Bartter approach to acid-base disturbances. In addition, the Stewart approach is much more complex and may be more prone to error, given its reliance upon multiple measurements of several variables. When measurements obtained from automated blood chemistry devices are used to calculate SIG, the results can also vary substantially depending on which device is used [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/14\">",
"     14",
"    </a>",
"    ]. We therefore prefer the traditional approach in the analysis of all acid-base disturbances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Relative diagnostic efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some evidence has suggested that the Stewart approach provides more accurate analysis of acid-base disturbances than the traditional approach. One study of 255 patients in a pediatric intensive care unit who had simultaneous measurements of arterial blood gases, electrolytes, and serum albumin concentration found that 26 percent of patients had a different interpretation of acid-base balance when the Stewart approach was used compared to when the conventional approach was used [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/12\">",
"     12",
"    </a>",
"    ]. The Stewart method was superior to the traditional method in identifying patients with high lactate levels.",
"   </p>",
"   <p>",
"    However, this benefit vanishes when hypoalbuminemia, a common problem in hospitalized patients, is accurately considered when using the conventional approach. To best understand this, a brief review of traditional analysis using the anion gap (AG) is required.",
"   </p>",
"   <p>",
"    In the evaluation of metabolic acidosis, the AG serves to differentiate a hyperchloremic acidosis (normal gap) from high AG acidosis associated with increased concentrations of nonvolatile anions other than chloride [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/15\">",
"     15",
"    </a>",
"    ]. Negative charges on plasma albumin are a large component of the unmeasured anions that contribute to the calculated AG in normal subjects. Thus, the presence of hypoalbuminemia, if not considered, will mask the presence of an organic acidosis when the clinician relies upon the AG for analysis.",
"   </p>",
"   <p>",
"    It is possible to adjust for the effect of low serum levels of albumin [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Each 1.0",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    decrease or increase in serum albumin below or above 4.4",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    respectively lowers or raises the actual concentration of unmeasured anions by approximately 2.3 to 2.5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/13\">",
"     13",
"    </a>",
"    ]. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=see_link\">",
"     \"Approach to the adult with metabolic acidosis\"",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    With appropriate adjustments for hypoalbuminemia, the traditional and Stewart approach are similarly accurate [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. This was shown in a study of 50 consecutive patients with metabolic acidosis who were admitted to a critical care unit [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/18\">",
"     18",
"    </a>",
"    ]. There was no advantage of the Stewart approach over the traditional approach to acid-base disturbances augmented by the albumin-corrected AG. Although the uncorrected anion gap failed to detect increased blood lactate levels, there was a strong correlation (r2 = 0.932) between the strong ion gap and the albumin-corrected anion gap.",
"   </p>",
"   <p>",
"    Acid-base analyses based on the SID require multiple measurements of several variables, each subject to error. This may be a particular problem when point of care measurements are used for these measurements because of the larger errors associated with these devices [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prognostic value",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data concerning the relative prognostic value of the Stewart versus the traditional approach; however, on average, the AG corrected for albumin and SIG perform equally well in predicting mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of 255 patients in a pediatric intensive care unit who had simultaneous measurements of arterial blood gases, electrolytes and serum albumin, 26 percent of patients had a different interpretation of acid-base balance when the Stewart approach was used compared to when the conventional approach was used [",
"      <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/12\">",
"       12",
"      </a>",
"      ]. The Stewart approach was more strongly associated with mortality than were the anion gap or plasma lactate level.",
"     </li>",
"     <li>",
"      By comparison, a study of 100 consecutive adults admitted to an intensive care unit found that traditional acid-base indices (lactate, AG, and pH) accurately discriminated between survivors and nonsurvivors [",
"      <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/21\">",
"       21",
"      </a>",
"      ]. The calculation of SIG, SIDeff, and SIDapp offered no advantage as prognostic markers.",
"     </li>",
"     <li>",
"      A study of 78 consecutive adults admitted to an intensive care unit for hemorrhagic shock caused by major trauma found that indicators of unmeasured anions (AG or SIG) were strongly associated with hospital mortality whereas pH and lactate were of limited value as predictors; the source of the unmeasured anions that are generated by critical illness has not been defined [",
"      <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/22\">",
"       22",
"      </a>",
"      ]. SIG performed slightly better than either the AG or the AG corrected for albumin in predicting mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/22\">",
"       22",
"      </a>",
"      ]. However, statistical comparisons between these measures are difficult because the variables used to calculate them are interconnected [",
"      <a class=\"abstract\" href=\"UTD.htm?19/61/20437/abstract/7,23\">",
"       7,23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most internists use the traditional approach to acid-base analysis, which relies upon the definition of the hydrogen ion concentration in blood as a function of the ratio between the PCO2 and the serum bicarbonate concentration. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cardinal tenet of the strong ion difference or Stewart approach to acid-base analysis is that the serum bicarbonate concentration does not alter blood pH. Instead, the independent variables responsible for changes in acid-base balance are the strong ion difference (SID), plasma concentration of nonvolatile weak acids or buffers (ATot), and arterial carbon dioxide tension (PaCO2). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Strong ion difference'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because clinically important acid-base derangements are thought to result from changes in PaCO2, SID, and ATot, the strong ion approach distinguishes six primary acid-base disturbances. These are respiratory acidosis, respiratory alkalosis, strong ion acidosis, strong ion alkalosis, nonvolatile buffer ion acidosis, and nonvolatile buffer ion alkalosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Strong ion difference'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The apparent SID (SIDapp) is defined as the difference in net charge between the sum of the strong cations and the sum of the major strong anions present in health.",
"     </li>",
"     <li>",
"      The calculated SID value, which is a function of pH and ATot, is called the effective strong ion difference or SIDeff. It can be calculated from measured values of pH, serum albumin, and phosphate (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Strong ion gap'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The difference between SIDapp and SIDeff is the strong ion gap, which should be zero. A positive value suggests that an organic acidosis may be present. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Strong ion gap'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major practical difference between the Stewart approach and the conventional approach to acid-base disturbances is the inclusion of the serum albumin concentration in the Stewart approach. However, if changes in serum albumin concentration are accounted for in measurement of the anion gap, the more complex Stewart approach does not appear to offer a clinically significant advantage over the traditional Schwartz-Bartter approach to acid-base disturbances. Each 1.0",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      decrease or increase in serum albumin below or above 4.4",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      respectively lowers or raises the actual concentration of unmeasured anions by approximately 2.3 to 2.5",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Relative diagnostic efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these considerations, we prefer the traditional approach in the analysis of acid-base disturbances.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/1\">",
"      RELMAN AS. What are acids and bases? Am J Med 1954; 17:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/2\">",
"      SCHWARTZ WB, RELMAN AS. A critique of the parameters used in the evaluation of acid-base disorders. \"Whole-blood buffer base\" and \"standard bicarbonate\" compared with blood pH and plasma bicarbonate concentration. N Engl J Med 1963; 268:1382.",
"     </a>",
"    </li>",
"    <li>",
"     Stewart, P. How to understand acid-base. Elsevier, New York, 1981.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/4\">",
"      Stewart PA. Modern quantitative acid-base chemistry. Can J Physiol Pharmacol 1983; 61:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/5\">",
"      Fencl V, Leith DE. Stewart's quantitative acid-base chemistry: applications in biology and medicine. Respir Physiol 1993; 91:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/6\">",
"      Kellum JA. Disorders of acid-base balance. Crit Care Med 2007; 35:2630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/7\">",
"      Rastegar A. Clinical utility of Stewart's method in diagnosis and management of acid-base disorders. Clin J Am Soc Nephrol 2009; 4:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/8\">",
"      Corey HE. Stewart and beyond: new models of acid-base balance. Kidney Int 2003; 64:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/9\">",
"      Figge J, Mydosh T, Fencl V. Serum proteins and acid-base equilibria: a follow-up. J Lab Clin Med 1992; 120:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/10\">",
"      Watson PD. Modeling the effects of proteins on pH in plasma. J Appl Physiol 1999; 86:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/11\">",
"      Carreira F, Anderson RJ. Assessing metabolic acidosis in the intensive care unit: does the method make a difference? Crit Care Med 2004; 32:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/12\">",
"      Balasubramanyan N, Havens PL, Hoffman GM. Unmeasured anions identified by the Fencl-Stewart method predict mortality better than base excess, anion gap, and lactate in patients in the pediatric intensive care unit. Crit Care Med 1999; 27:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/13\">",
"      Feldman M, Soni N, Dickson B. Influence of hypoalbuminemia or hyperalbuminemia on the serum anion gap. J Lab Clin Med 2005; 146:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/14\">",
"      Nguyen BV, Vincent JL, Hamm JB, et al. The reproducibility of Stewart parameters for acid-base diagnosis using two central laboratory analyzers. Anesth Analg 2009; 109:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/15\">",
"      Emmett M, Narins RG. Clinical use of the anion gap. Medicine (Baltimore) 1977; 56:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/16\">",
"      Figge J, Jabor A, Kazda A, Fencl V. Anion gap and hypoalbuminemia. Crit Care Med 1998; 26:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/17\">",
"      Corey HE. The anion gap (AG): studies in the nephrotic syndrome and diabetic ketoacidosis (DKA). J Lab Clin Med 2006; 147:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/18\">",
"      Moviat M, van Haren F, van der Hoeven H. Conventional or physicochemical approach in intensive care unit patients with metabolic acidosis. Crit Care 2003; 7:R41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/19\">",
"      Dubin A, Menises MM, Masevicius FD, et al. Comparison of three different methods of evaluation of metabolic acid-base disorders. Crit Care Med 2007; 35:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/20\">",
"      Morimatsu H, Rockt&auml;schel J, Bellomo R, et al. Comparison of point-of-care versus central laboratory measurement of electrolyte concentrations on calculations of the anion gap and the strong ion difference. Anesthesiology 2003; 98:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/21\">",
"      Cusack RJ, Rhodes A, Lochhead P, et al. The strong ion gap does not have prognostic value in critically ill patients in a mixed medical/surgical adult ICU. Intensive Care Med 2002; 28:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/22\">",
"      Kaplan LJ, Kellum JA. Comparison of acid-base models for prediction of hospital mortality after trauma. Shock 2008; 29:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20437/abstract/23\">",
"      Kurtz I, Kraut J, Ornekian V, Nguyen MK. Acid-base analysis: a critique of the Stewart and bicarbonate-centered approaches. Am J Physiol Renal Physiol 2008; 294:F1009.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2311 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-3EAB60D91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_61_20437=[""].join("\n");
var outline_f19_61_20437=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRONG ION DIFFERENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Strong ion gap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      STRONG ION VERSUS TRADITIONAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Relative diagnostic efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prognostic value",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2311\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2311|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/58/939\" title=\"table 1\">",
"      Effective strong ion difference",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31432?source=related_link\">",
"      Approach to the adult with metabolic acidosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_61_20438="Methylene blue: Pediatric drug information";
var content_f19_61_20438=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Methylene blue: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"    see \"Methylene blue: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/6/39012?source=see_link\">",
"    see \"Methylene blue: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1060314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Cyanide",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Drug-induced Methemoglobinemia",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12675219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Systemic doses as low as 2 mg/kg have been associated with hemolytic anemia and skin desquamation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methemoglobinemia: I.V.: 1-2 mg/kg (0.1-0.2 mL/kg of 1% solution) (Clifton, 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Shock (vasodilatory) with hypotension unresponsive to fluid resuscitation, exogenous catecholamines and corticosteroids: Limited data available; further studies needed: I.V.: 1 mg/kg/dose; dosing based on a case series of five neonates (preterm: n=4; GA: 23-30 weeks) with presumed septic shock (Driscoll, 1996)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1060310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"      see \"Methylene blue: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Methemoglobinemia: Infants, Children, and Adults: I.V.: 1-2 mg/kg or 25-50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ; may be repeated after 1 hour if necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chronic methemoglobinemia: Adults: Oral: 100-300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     NADPH-methemoglobin reductase deficiency: Children: Oral: 1-1.5 mg/kg/day (maximum dose: 300 mg/day) given with 5-8 mg/kg/day ascorbic acid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary antiseptic: Adults: Oral: 65-130 mg 3 times/day; maximum dose: 390 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chronic urolithiasis: Adults: Oral: 65 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ifosfamide-induced encephalopathy: Adults: Oral, I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Treatment may not be necessary; encephalopathy may improve spontaneously",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prevention: 50 mg every 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment: 50 mg as a single dose or every 4-8 hours until symptoms resolve",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F195153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10 mg/mL (1 mL, 10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F195142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1060317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer after meals with a full glass of water; may be mixed with fruit juice to mask unpleasant taste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Administer undiluted by direct I.V. injection over several minutes; when administered for the treatment of ifosfamide-induced encephalopathy, may be administered either undiluted as a slow I.V. push over at least 5 minutes or diluted in 50 mL NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W and infused over at least 5 minutes; may be administered intraosseously",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F8018003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1060316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antidote for cyanide poisoning and drug-induced methemoglobinemia (FDA approved use), indicator dye, bacteriostatic genitourinary antiseptic; other uses include treatment/prevention of ifosfamide-induced encephalopathy; topically, in conjunction with polychromatic light to photoinactivate viruses such as herpes simplex; alone or in combination with vitamin C for the management of chronic urolithiasis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F195181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Due to the potential for dosing errors between mg and mL of methylene blue, prescribing and dosing should only be expressed in terms of mg of methylene blue (and not as mL)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Due to potential toxicity (hemolytic anemia), do not use methylene blue to color enteral feedings to detect aspiration.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F195179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, arrhythmia, hypertension, precordial pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, fever, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Staining of skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, fecal discoloration (blue-green), nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Bladder irritation, discoloration of urine (blue-green)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Anemia, transient reduction in oxygen saturation as read by pulse oximetry",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Serotonin syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1060320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to methylene blue or any component; renal insufficiency; intraspinal injection",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1060309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in young patients (eg, infants, neonates) and in patients with severe renal insufficiency or G-6-PD deficiency; at high doses or in patients with G-6-PD-deficiency and infants, methylene blue may catalyze the oxidation of ferrous iron in hemoglobin to ferric iron causing paradoxical methemoglobinemia; monitor methemoglobin concentrations regularly during administration. Inject slowly to avoid high local concentrations and the production of methemoglobin; large I.V. doses have been associated with precordial pain and hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1060308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not inject subcutaneously or intrathecally as necrotic abscesses (SubQ) and neural damage (I.T.) including paraplegia have occurred. Methylene blue should not be added to enteral feeding products (Wessel, 2005); safety and efficacy has not been established. Serotonin syndrome has been reported with concomitant administration of methylene blue and serotonin reuptake inhibitors (eg, SSRIs, SNRIs, tricyclic antidepressants); avoid concomitant use and allow a washout period of at least 4-5 half-lives of the serotonin reuptake inhibitor prior to intravenous methylene blue use.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     Monoamine Oxidase",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): MAO Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Indirect-Acting): MAO Inhibitors may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: MAO Inhibitors may enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists (Ophthalmic): MAO Inhibitors may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of MAO Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: MAO Inhibitors may enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome. Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: MAO Inhibitors may enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: MAO Inhibitors may enhance the neurotoxic (central) effect of AtoMOXetine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: MAO Inhibitors may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May enhance the adverse/toxic effect of MAO Inhibitors. Management: Avoid concurrent use of carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclobenzaprine: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: MAO Inhibitors may enhance the hypertensive effect of Dexmethylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: MAO Inhibitors may enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diethylpropion: MAO Inhibitors may enhance the hypertensive effect of Diethylpropion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxapram: MAO Inhibitors may enhance the hypertensive effect of Doxapram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HYDROmorphone: MAO Inhibitors may enhance the adverse/toxic effect of HYDROmorphone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: MAO Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: May enhance the adverse/toxic effect of MAO Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: MAO Inhibitors may enhance the adverse/toxic effect of Linezolid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: MAO Inhibitors may enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maprotiline: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: MAO Inhibitors may enhance the serotonergic effect of Meperidine. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: MAO Inhibitors may enhance the adverse/toxic effect of Methadone.  Management: Initial safety testing, where small incremental doses of methadone are given with the patient closely monitored (including vitals, etc.), is recommended if methadone is to be used with (or within 14 days of) an MAO inhibitor. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: MAO Inhibitors may enhance the hypertensive effect of Methylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orthostatic Hypotension Producing Agents: MAO Inhibitors may enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxymorphone: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pizotifen: MAO Inhibitors may enhance the anticholinergic effect of Pizotifen.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: MAO Inhibitors may enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension).  Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: MAO Inhibitors may decrease the metabolism of Serotonin 5-HT1D Receptor Agonists.  Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Eletriptan; Frovatriptan; Naratriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrahydrozoline (Nasal): MAO Inhibitors may enhance the hypertensive effect of Tetrahydrozoline (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors. Management: Consider alternatives to combined treatment with tramadol and monoamine oxidase inhibitors due to an increased risk of serotonin syndrome and seizures. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: MAO Inhibitors may enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F195150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use during amniocentesis has shown evidence of fetal abnormalities (atresia of the ileum and jejunum, ileal occlusions, and other adverse effects); has been used orally without similar adverse events; use, however, is contraindicated in women who are or may become pregnant. In general, medications used as antidotes should take into consideration the health and prognosis of the mother.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8018064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC; of note, pulse oximetry is not reliable as methylene blue interferes with light emission, resulting in falsely depressed readings",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1060307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Weak germicide; in low concentrations hastens the conversion of methemoglobin to hemoglobin; has opposite effect at high concentrations by converting ferrous iron of reduced hemoglobin to ferric iron to form methemoglobin; in cyanide toxicity, it combines with cyanide to form cyanmethemoglobin preventing the interference of cyanide with the cytochrome system",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1060319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well-absorbed from GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability, oral: 50% to 100%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak effect: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Peripheral reduction to leukomethylene blue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In bile, feces, and urine as leukomethylene blue",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1060313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/6/39012?source=see_link\">",
"      see \"Methylene blue: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May discolor urine and feces blue-green; may discolor skin on contact",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1060321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Has been used topically (0.1% solutions) in conjunction with polychromatic light to photoinactivate viruses such as herpes simplex; has been used alone or in combination with vitamin C for the management of chronic urolithiasis; skin stains may be removed using a hypochlorite solution",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Albert M, Lessin MS, and Gilchrist BF, \"Methylene Blue: Dangerous Dye for Neonates,\"",
"      <i>",
"       J Pediatr Surg",
"      </i>",
"      , 2003, 38(8):1244-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/61/20438/abstract-text/12891503/pubmed\" id=\"12891503\" target=\"_blank\">",
"        12891503",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clifton J 2nd and Leikin JB, \"Methylene Blue,\"",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 2003, 10(4):289-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/61/20438/abstract-text/12845393/pubmed\" id=\"12845393\" target=\"_blank\">",
"        12845393",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      David KA and Picus J, &ldquo;Evaluating Risk Factors for the Development of Ifosfamide Encephalopathy,&rdquo;",
"      <i>",
"       Am J Clin Oncol",
"      </i>",
"      , 2005, 28(3):277-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/61/20438/abstract-text/15923801/pubmed\" id=\"15923801\" target=\"_blank\">",
"        15923801",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Driscoll W, Thurin S, Carrion V, et al, \"Effect of Methylene Blue on Refractory Neonatal Hypotension,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1996, 129(6):904-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/61/20438/abstract-text/8969734/pubmed\" id=\"8969734\" target=\"_blank\">",
"        8969734",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maloney JP, Ryan TA, Brasel KJ, et al, \"Food Dye Use in Enteral Feedings: A Review and a Call for a Moratorium,\"",
"      <i>",
"       Nutr Clin Pract",
"      </i>",
"      , 2002, 17(3):169-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/61/20438/abstract-text/16214982/pubmed\" id=\"16214982\" target=\"_blank\">",
"        16214982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ofoegbu BN, Agarwal RP, and Lewis MA, \"Methylene Blue Irrigation-Treatment of Renal Fungal Balls Causing Acute Renal Failure in a Preterm Infant,\"",
"      <i>",
"       Acta Paediatr",
"      </i>",
"      , 2007, 96(6):939-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/61/20438/abstract-text/17537031/pubmed\" id=\"17537031\" target=\"_blank\">",
"        17537031",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Patel PN, &ldquo;Methylene Blue for Management of Ifosfamide-Induced Encephalopathy,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2006, 40(2):299-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/61/20438/abstract-text/16391008/pubmed\" id=\"16391008\" target=\"_blank\">",
"        16391008",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pelgrims J, DeVos F, Van den Brande J, et al, &ldquo;Methylene Blue in the Treatment and Prevention of Ifosfamide-Induced Encephalopathy: Report of 12 Cases and a Review of the Literature,&rdquo;",
"      <i>",
"       Br J Cancer",
"      </i>",
"      , 2000, 82(2) 291-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/61/20438/abstract-text/10646879/pubmed\" id=\"10646879\" target=\"_blank\">",
"        10646879",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sills MR and Zinkham WH, \"Methylene Blue-Induced Heinz Body Hemolytic Anemia,\"",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 1994, 148(3):306-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/61/20438/abstract-text/8130867/pubmed\" id=\"8130867\" target=\"_blank\">",
"        8130867",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wessel J, Balint J, Crill C, et al, \"Standards for Specialized Nutrition Support: Hospitalized Pediatric Patients,\"",
"      <i>",
"       Nutr Clin Pract",
"      </i>",
"      , 2005, 20(1):103-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?19/61/20438/abstract-text/16207652/pubmed\" id=\"16207652\" target=\"_blank\">",
"        16207652",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12599 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-906C751B57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_61_20438=[""].join("\n");
var outline_f19_61_20438=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060314\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12675219\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060310\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195153\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195142\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060317\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018003\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060316\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195181\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195179\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060320\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060309\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060308\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299700\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221635\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F195150\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079758\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8018064\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060307\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060319\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060313\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1060321\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12599\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12599|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=related_link\">",
"      Methylene blue: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/6/39012?source=related_link\">",
"      Methylene blue: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_61_20439="Atypical adenomatous hyperplasia";
var content_f19_61_20439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F55484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F55484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atypical adenomatous hyperplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 538px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) This 3-mm nodular lesion consists of atypical pneumocytes proliferating along preexisting alveolar walls. There is no invasive component.",
"    <br>",
"     (B) The slightly atypical pneumocytes are cuboidal and show gaps between the cells. Nuclei are hyperchromatic, and a few show nuclear enlargement and multinucleation.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol 2011; 6:244. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_61_20439=[""].join("\n");
var outline_f19_61_20439=null;
var title_f19_61_20440="Shoulder bursitis US PMR";
var content_f19_61_20440=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F86316%7ERHEUM%2F50236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F86316%7ERHEUM%2F50236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 638px\">",
"   <div class=\"ttl\">",
"    Sonogram of shoulder bursitis in polymyalgia rheumatica",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 618px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The left panel shows an anterior longitudinal sonogram of the shoulder in a patient with polymyalgia rheumatica. Fluid is present within the distended subacromial-subdeltoid bursa (*). The right panel shows an anterior transverse sonogram of the same shoulder, with power Doppler signals indicating active inflammation of the bursal sheaths (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George AW Bruyn, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Transverse sonogram of rotator cuff tear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 358px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This transverse sonogram of the shoulder shows a full-thickness rotator cuff tear (arrows) and associated fluid-filled subdeltoid bursa (asterisks).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of George AW Bruyn, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_61_20440=[""].join("\n");
var outline_f19_61_20440=null;
var title_f19_61_20441="Management of moderate and severe alcohol withdrawal syndromes";
var content_f19_61_20441=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of moderate and severe alcohol withdrawal syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/61/20441/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/61/20441/contributors\">",
"     Robert S Hoffman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/61/20441/contributors\">",
"     Gerald L Weinhouse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/61/20441/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/61/20441/contributors\">",
"     Stephen J Traub, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/61/20441/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/61/20441/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/61/20441/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcoholism is such a common condition that virtually every clinician is confronted with its complications. There are an estimated 8 million alcohol dependent people in the United States. Approximately 500,000 episodes of withdrawal severe enough to require pharmacologic treatment occur each year [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The in-patient management of syndromes associated with moderate and severe alcohol withdrawal is reviewed here. The ambulatory management of mild alcohol withdrawal, the initial diagnosis and treatment of alcohol dependence, and specific conditions due to alcohol-related organ damage (eg, cirrhosis, pancreatitis) are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=see_link\">",
"     \"Ambulatory alcohol detoxification\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=see_link\">",
"     \"Pharmacotherapy for alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=see_link\">",
"     \"Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39575?source=see_link\">",
"     \"Etiology and pathogenesis of chronic pancreatitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4710?source=see_link\">",
"     \"Alcohol abuse and hematologic disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=see_link\">",
"     \"Brief intervention for unhealthy alcohol and other drug use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not entirely clear why some individuals suffer from more severe withdrawal symptoms than others, but genetic predisposition may play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/2\">",
"     2",
"    </a>",
"    ]. Experiments in 1955 demonstrated that alcohol-naive volunteers given continual alcohol for longer periods developed more severe withdrawal than those who drank for shorter periods [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/3\">",
"     3",
"    </a>",
"    ]. These results imply that most people are vulnerable to the effects of the abrupt cessation of prolonged, sustained ethanol intake. However, withdrawal usually does not occur in the general population because most people drink in an episodic fashion that does not lead to the sustained high blood concentrations of alcohol necessary to develop tolerance and withdrawal.",
"   </p>",
"   <p>",
"    Symptoms of alcohol withdrawal occur because alcohol is a central nervous system depressant. Alcohol simultaneously enhances inhibitory tone (via modulation of gamma-aminobutyric acid activity) and inhibits excitatory tone (via modulation of excitatory amino acid activity). Only the constant presence of ethanol preserves homeostasis. Abrupt cessation unmasks the adaptive responses to chronic ethanol use resulting in overactivity of the central nervous system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Gamma-aminobutyric acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the brain. Highly specific binding sites for ethanol are found on the GABA receptor complex [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/4\">",
"     4",
"    </a>",
"    ]. Chronic ethanol use induces an insensitivity to GABA such that more inhibitor is required to maintain a constant inhibitory tone [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/5\">",
"     5",
"    </a>",
"    ]. As alcohol tolerance develops, the individual retains arousal at concentrations which would normally produce lethargy or even coma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Excitatory amino acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glutamate is one of the major excitatory amino acids. When glutamate binds to the N-methyl-D-aspartate (NMDA) receptor, calcium influx leads to neuronal excitation. Ethanol inhibits glutamate induced excitation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Adaption occurs by increasing sensitivity to glutamate in an attempt to maintain a normal state of arousal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MINOR WITHDRAWAL SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor withdrawal symptoms are due to central nervous system hyperactivity, and can include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Insomnia",
"     </li>",
"     <li>",
"      Tremulousness",
"     </li>",
"     <li>",
"      Mild anxiety",
"     </li>",
"     <li>",
"      Gastrointestinal upset; anorexia",
"     </li>",
"     <li>",
"      Headache",
"     </li>",
"     <li>",
"      Diaphoresis",
"     </li>",
"     <li>",
"      Palpitations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms are usually present within six hours of the cessation of drinking and may develop while patients still have a significant blood alcohol concentration (",
"    <a class=\"graphic graphic_table graphicRef75499 \" href=\"UTD.htm?12/5/12379\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/8\">",
"     8",
"    </a>",
"    ]. If withdrawal does not progress, these findings resolve within 24 to 48 hours. The specific minor withdrawal symptoms in a given patient typically are consistent from one episode to the next. The ambulatory management of mild alcohol withdrawal, including criteria to determine which patients are suitable for out-patient management, is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=see_link\">",
"     \"Ambulatory alcohol detoxification\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     WITHDRAWAL SEIZURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Withdrawal-associated seizures are generalized tonic-clonic convulsions that usually occur within 12 to 48 hours after the last drink, but may occur after only two hours of abstinence (",
"    <a class=\"graphic graphic_table graphicRef75499 \" href=\"UTD.htm?12/5/12379\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/9\">",
"     9",
"    </a>",
"    ]. The seizures occur predominantly in patients with a long history of chronic alcoholism.",
"   </p>",
"   <p>",
"    Withdrawal seizures are usually singular or occur as a brief flurry over a short period. Recurrent or prolonged seizures or status epilepticus should prompt an investigation into possible structural or infectious etiologies, generally guided by the findings of cranial computed tomography (CT) or lumbar puncture. Benzodiazepines and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    can be used to treat status epilepticus while investigations proceed. Several studies have demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    is ineffective in the treatment of alcohol withdrawal seizures and the drug should not be used for this purpose [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=see_link\">",
"     \"Evaluation of the first seizure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although seemingly benign, alcohol withdrawal seizures left untreated progress to delirium tremens in nearly one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Delirium tremens (DT)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ALCOHOLIC HALLUCINOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite a tendency to equate alcoholic hallucinosis with delirium tremens, the two terms are NOT synonymous. Alcoholic hallucinosis refers to hallucinations that develop within 12 to 24 hours of abstinence and resolve within 24 to 48 hours (which is the earliest point at which delirium tremens typically develops) (",
"    <a class=\"graphic graphic_table graphicRef75499 \" href=\"UTD.htm?12/5/12379\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/13\">",
"     13",
"    </a>",
"    ]. Hallucinations are usually visual, although auditory and tactile phenomena may also occur. In contrast to delirium tremens, alcoholic hallucinosis is not associated with global clouding of the sensorium, but with specific hallucinations, and vital signs are usually normal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42569?source=see_link&amp;anchor=H10#H10\">",
"     \"Approach to the patient with visual hallucinations\", section on 'Alcohol and drug use'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DELIRIUM TREMENS (DT)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clinical manifestations of severe withdrawal and DT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delirium tremens (DT) is defined by hallucinations, disorientation, tachycardia, hypertension, fever, agitation, and diaphoresis in the setting of acute reduction or abstinence from alcohol. In the absence of complications, symptoms of DT can persist for up to seven days.",
"   </p>",
"   <p>",
"    Patients with DT have significantly elevated cardiac indices, oxygen delivery, and oxygen consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/14\">",
"     14",
"    </a>",
"    ]. Arterial pH rises due to hyperventilation, which may be a rebound effect related to the respiratory depressant properties of alcohol. Hyperventilation and consequent respiratory alkalosis in this setting result in a significant decrease in cerebral blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/15\">",
"     15",
"    </a>",
"    ]. There is a correlation between the length of the preceding alcohol binge, the degree of clouding of the sensorium, and the size of the average decrease in cerebral hemispheric blood flow, although there is no association between blood flow parameters and hallucinations or tremors [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe alcohol withdrawal may have an important impact on fluid and electrolyte status. Almost all patients in acute withdrawal are hypovolemic as a result of diaphoresis, hyperthermia, vomiting, and tachypnea. Hypokalemia is common due to renal and extrarenal losses, alterations in aldosterone levels, and changes in potassium distribution across the cell membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Hypomagnesemia is common in patients with DT and may predispose to dysrhythmia and seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/18\">",
"     18",
"    </a>",
"    ]. Hypophosphatemia may occur due to malnutrition, may be symptomatic, and if severe, may contribute to cardiac failure and rhabdomyolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 percent of patients who undergo withdrawal from alcohol suffer from DT. DT typically begins between 48 and 96 hours after the last drink and lasts one to five days (",
"    <a class=\"graphic graphic_table graphicRef75499 \" href=\"UTD.htm?12/5/12379\">",
"     table 1",
"    </a>",
"    ). DT and alcoholic hallucinosis are NOT synonymous and symptoms that occur a few hours after the cessation of drinking, even if severe, are not manifestations of DT. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Alcoholic hallucinosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Risk factors for the development of DT include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A history of sustained drinking",
"     </li>",
"     <li>",
"      A history of previous DT",
"     </li>",
"     <li>",
"      Age greater than 30",
"     </li>",
"     <li>",
"      The presence of a concurrent illness",
"     </li>",
"     <li>",
"      The presence of significant alcohol withdrawal in the presence of an elevated alcohol level",
"     </li>",
"     <li>",
"      A longer period since the last drink (ie, patients who present with alcohol withdrawal more than two days after their last drink are more likely to experience DT than those who present within two days)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;DT is associated with a mortality rate of up to 5 percent. This figure has diminished from a 37 percent mortality rate reported in the early twentieth century, probably as a result of earlier diagnosis, improvements in supportive and pharmacologic therapies, and improved treatment of comorbid illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/2,22-26\">",
"     2,22-26",
"    </a>",
"    ]. Death usually is due to arrhythmia, complicating illnesses, such as pneumonia, or failure to identify an underlying problem that led to the cessation of alcohol use, such as pancreatitis, hepatitis, or central nervous system injury or infection. Older age, preexisting pulmonary disease, core body temperature greater than 40&ordm;C (104&ordm;F), and coexisting liver disease are associated with a greater risk of mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Rule out alternative diagnoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alcohol withdrawal remains a clinical diagnosis. It may be necessary to perform extensive testing, including lumbar puncture and cranial CT, to rule out other diagnostic considerations with confidence. This is particularly true when the presentation includes altered mental status and fever. Conditions, such as infection (eg, meningitis), trauma (eg, intracranial hemorrhage), metabolic derangements, drug overdose, hepatic failure, and gastrointestinal bleeding, can mimic or coexist with alcohol withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/28\">",
"     28",
"    </a>",
"    ]. A premature diagnosis of alcohol withdrawal can lead to inappropriate use of sedatives, which can further delay accurate diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Symptom control and supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once comorbid illnesses have been excluded or adequately treated, the management of alcohol withdrawal is directed at alleviating symptoms and identifying and correcting metabolic derangements. Benzodiazepines are used to control psychomotor agitation and prevent progression to more severe withdrawal. Supportive care, including intravenous fluids, nutritional supplementation, and frequent clinical reassessment including vital signs, is important. Clinicians must avoid complacency when treating patients with alcohol withdrawal. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment of psychomotor agitation with benzodiazepines'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20\">",
"     'Symptom-triggered therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients should be placed in a quiet, protective environment. Mechanical restraint may be necessary temporarily for patients suffering from delirium tremens (DT) in order to protect both the patient and caretakers. Clinicians should follow their facility's guidelines for documentation and implementation of physical restraints. Once adequate chemical sedation is achieved, physical restraints should be removed, as resistance against restraints can increase temperature, produce rhabdomyolysis, and cause physical injury.",
"   </p>",
"   <p>",
"    Volume deficits can be calculated and replaced accordingly, or, if there are no contraindications, isotonic intravenous fluid can be infused rapidly until patients are clinically euvolemic. Thiamine and glucose should be administered in order to prevent or treat Wernicke's encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Multivitamins containing or supplemented with folate should be given routinely, and deficiencies of glucose, potassium, magnesium, and phosphate should be corrected as needed. Initially (first day or two), treatment should be intravenous as gastrointestinal absorption is impaired in many patients who abuse alcohol chronically. The details of these supportive treatments are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=see_link&amp;anchor=H14#H14\">",
"     \"Wernicke's encephalopathy\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40328?source=see_link\">",
"     \"Overview of the chronic neurologic complications of alcohol\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=see_link\">",
"     \"Clinical manifestations and treatment of hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2167?source=see_link\">",
"     \"Diagnosis and treatment of hypophosphatemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some clinicians treat alcohol withdrawal patients with an intravenous infusion of a combination of thiamine, folate, and a multivitamin in isotonic saline with 5 percent dextrose. The multivitamin makes the fluid appear yellow, and thus, this treatment combination is sometimes referred to as a &ldquo;banana bag&rdquo;. Use of this treatment has not been well studied, and it may not meet the requirements for fluid, glucose, and other substrates of many patients with alcohol withdrawal.",
"   </p>",
"   <p>",
"    During the early phases of withdrawal alcoholic patients are often given nothing by mouth (ie, NPO) to prevent aspiration [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/32\">",
"     32",
"    </a>",
"    ]. However, nutritional support is essential as alcoholic patients are frequently malnourished and have high metabolic needs due to their excited autonomic state. Initially, glucose supplementation is sufficient, but additional nutrition is needed for patients who remain unable to eat for more than a day or two. Patients considered at high risk for complications should be monitored in an intensive care unit (",
"    <a class=\"graphic graphic_table graphicRef73377 \" href=\"UTD.htm?31/49/32539\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=see_link\">",
"     \"Nutrition support in critically ill patients: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment of psychomotor agitation with benzodiazepines",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Drug selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines are used to treat the psychomotor agitation most patients experience during withdrawal and to prevent progression from minor withdrawal symptoms to major ones [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/22-25,28,32-37\">",
"     22-25,28,32-37",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     Diazepam",
"    </a>",
"    (Valium),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    (Ativan), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     chlordiazepoxide",
"    </a>",
"    (Librium) are used most frequently to treat or prevent alcohol withdrawal, but other benzodiazepines may be used [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/38\">",
"     38",
"    </a>",
"    ]. In general, long-acting benzodiazepines with active metabolites (eg, diazepam) are preferred because they seem to result in a smoother course with less chance of recurrent withdrawal or seizures. We recommend a symptom-triggered approach to treatment with benzodiazepines. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Symptom-triggered therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    (Ativan) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"     oxazepam",
"    </a>",
"    (Serax) for the treatment of patients with advanced cirrhosis. The shorter half-life of lorazepam and the absence of active metabolites with oxazepam may prevent prolonged effects if oversedation occurs. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     chlordiazepoxide",
"    </a>",
"    has a relatively long half-life and may lead to oversedation in patients with severe liver disease. Treatment with agents available in parenteral form (eg, lorazepam,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ) may be necessary in patients who cannot receive oral medications.",
"   </p>",
"   <p>",
"    Given the recent trend of drug shortages, preferred agents may not always be available. A treatment algorithm for clinicians managing moderate or severe alcohol withdrawal without access to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    is provided (",
"    <a class=\"graphic graphic_algorithm graphicRef53322 \" href=\"UTD.htm?24/4/24641\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Benzodiazepines exert their effect via stimulation of gamma-aminobutyric acid (GABA) receptors, causing a decrease in neuronal activity and relative sedation. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Gamma-aminobutyric acid'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Route",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with seizures or DT require intravenous (IV) therapy with benzodiazepines. IV therapy is appropriate for the initial management of most patients with tremulousness from alcohol withdrawal because of guaranteed absorption and rapidity of onset. It is important to have IV access in all patients at risk of severe withdrawal.",
"   </p>",
"   <p>",
"    Intramuscular administration should be avoided because of variable drug absorption. Oral formulations are preferred in most outpatient settings and for the prevention of withdrawal in asymptomatic patients known to be at risk. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Prophylaxis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=see_link\">",
"     \"Ambulatory alcohol detoxification\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Titration of medications should be based upon a given patient's risk factors for and ability to tolerate DT. As an example, a patient younger than 45 years with no comorbid illnesses should be lightly sedated to a degree that insures safety and comfort but does not obscure the neurologic examination. In contrast, an older patient with preexisting cardiopulmonary disease may benefit from heavier sedation, but must be closely monitored due to the greater risk imposed by the high systemic stress of major withdrawal or oversedation. Explicit criteria for ICU admission are provided (",
"    <a class=\"graphic graphic_table graphicRef73377 \" href=\"UTD.htm?31/49/32539\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A variety of dosing schedules can be used. We generally give IV",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    , 5 to 10 mg IV every 5 to 10 minutes, until the appropriate level of sedation is achieved.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    , 2 to 4 mg IV every 15 to 20 minutes, can also be used. In severe withdrawal, select patients may require massive doses (&gt;500 mg diazepam) to achieve initial control of symptoms, and continued aggressive use of benzodiazepines thereafter (&gt;2000 mg diazepam over 48 hours).",
"   </p>",
"   <p>",
"    Fixed schedule therapy, in which a benzodiazepine is given at fixed intervals even if symptoms are absent, is often administered despite a lack of strong supporting evidence. This strategy is most useful for preventing withdrawal in patients at risk, but asymptomatic or minimally symptomatic. The only advantage of this strategy is for the provider, as frequent reassessment is not required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Symptom-triggered therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We favor a symptom-triggered approach to the treatment of alcohol withdrawal that involves providing medication only when a patient has symptoms.",
"   </p>",
"   <p>",
"    To use this approach, a regular systematic assessment should be made of the patient's status using a validated instrument, such as the Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWAS-Ar), a measure of withdrawal severity (",
"    <a class=\"graphic graphic_table graphicRef64835 \" href=\"UTD.htm?20/61/21470\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/39\">",
"     39",
"    </a>",
"    ]. A calculator to determine this score is provided (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?33/0/33796?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). Evaluation intervals as frequent as every 10 to 15 minutes are appropriate for patients with more severe symptoms being treated with IV benzodiazepines. Once severe symptoms are controlled, hourly reassessment of such patients is reasonable. In contrast, an interval of four to six hours is reasonable for stable patients with mild symptoms receiving oral benzodiazepines.",
"   </p>",
"   <p>",
"    When the score is elevated, additional medication is given. For acute withdrawal, we give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    5 to 10 mg IV for any score of 8 or greater on the CIWAS-Ar.",
"   </p>",
"   <p>",
"    Multiple randomized and observational studies support this simple concept of giving the patient what they need, when they need it [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. Taken collectively, these studies demonstrate that symptom-triggered therapy achieves equivalent or superior clinical endpoints while requiring lower total doses of sedatives and shorter periods of hospitalization.",
"   </p>",
"   <p>",
"    In the landmark study of this approach, 101 patients admitted to an inpatient alcohol detoxification unit were randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     chlordiazepoxide",
"    </a>",
"    using a fixed schedule or a symptom-triggered therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/41\">",
"     41",
"    </a>",
"    ]. Patients in the symptom-triggered group required less medication (median 100 versus 425 mg) and a shorter treatment period (median 9 versus 68 hours).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Disposition and monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients being treated for moderate or severe alcohol withdrawal must be closely monitored and many require admission to an intensive care unit (ICU). A table of ICU admission criteria is provided (",
"    <a class=\"graphic graphic_table graphicRef73377 \" href=\"UTD.htm?31/49/32539\">",
"     table 2",
"    </a>",
"    ). Older patients are at greater risk for delirium tremens and may not tolerate the systemic stress of major withdrawal. Standard monitoring includes continual assessment of vital signs, pulse oximetry, fluid status, and neurological function. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Delirium tremens (DT)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Refractory delirium tremens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients have refractory delirium tremens despite treatment with high-dose benzodiazepines, possibly because of low endogenous GABA levels or acquired conformational changes in the GABA receptor [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Refractory delirium tremens is not clearly defined. It may be present if more than 50 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    or 10 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    is required to control the symptoms of severe withdrawal during the first hour of treatment, or if doses greater than 200 mg of diazepam or 40 mg of lorazepam fail to adequately control symptoms during the initial three to four hours of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/47\">",
"     47",
"    </a>",
"    ]. As with any dangerous intoxication, we recommend obtaining assistance from a medical toxicologist or poison control center in such instances. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Additional resources'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In patients with refractory delirium tremens, barbiturates (specifically",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ) can be very effective when given with benzodiazepines [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/47\">",
"     47",
"    </a>",
"    ]. We give phenobarbital 130 to 260 mg IV, repeated every 15 to 20 minutes, until symptoms are controlled.",
"   </p>",
"   <p>",
"    Benzodiazepines, which increase the frequency of GABA chloride channel opening, and barbiturates, which increase the duration of channel opening, may work synergistically.",
"   </p>",
"   <p>",
"    Another reasonable alternative is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    , which can act to open chloride channels in the absence of GABA, and may also antagonize the excitatory amino acids that are upregulated during alcohol withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Endotracheal intubation and mechanical ventilation are frequently necessary if",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    or propofol are used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Alternative and contraindicated agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    have been used with benzodiazepines or, rarely, alone to treat alcohol withdrawal. These agents are less well studied than benzodiazepines and may mask the hemodynamic signs of withdrawal, which can precede seizures. We believe they should",
"    <strong>",
"     not",
"    </strong>",
"    be used routinely in the treatment of moderate or severe alcohol withdrawal. Such drugs include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ethanol",
"     </li>",
"     <li>",
"      Antipsychotics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Anticonvulsants (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Centrally acting alpha-2 agonists (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beta blockers (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"       Baclofen",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these agents can reduce the frequency and intensity of minor withdrawal symptoms, but more data support the efficacy and safety of benzodiazepines in reducing the risk of seizures and delirium tremens.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ethanol &ndash; Ethanol should",
"      <strong>",
"       not",
"      </strong>",
"      be used as therapy in the setting of acute alcohol withdrawal. It is difficult to titrate, associated with many adverse metabolic and end-organ effects, and clearly inferior to benzodiazepines [",
"      <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antipsychotics &ndash; Phenothiazines and butyrophenones (including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      ) lower the seizure threshold and should",
"      <strong>",
"       not",
"      </strong>",
"      be used routinely in the withdrawing alcoholic [",
"      <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/51\">",
"       51",
"      </a>",
"      ]. These drugs may also interfere with heat dissipation and do not exhibit cross-tolerance with ethanol.",
"      <br/>",
"      <br/>",
"      Treatment with antipsychotics would only be appropriate when a decompensated thought disorder (such as schizophrenia) coexists with ethanol withdrawal and any symptoms associated with ethanol withdrawal have been definitively treated with benzodiazepines. In our experience, such occurrences are rare, even in patients with known thought disorders.",
"      <br/>",
"      <br/>",
"      If a clinician determines that antipsychotic therapy is indicated, we recommend an ECG to screen for QT prolongation (a contraindication to many antipsychotic medications) and the correction of electrolyte abnormalities (such as hypokalemia and hypomagnesemia, which are common in alcoholics)",
"      <strong>",
"       before",
"      </strong>",
"      any medication is administered.",
"     </li>",
"     <li>",
"      Anticonvulsants &ndash; Sustained anticonvulsant therapy has no role in patients with isolated alcohol withdrawal seizures. The overwhelming majority of seizures from withdrawal are self-limited and do not require treatment with anticonvulsants. If status epilepticus ensues,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      may be used for short-term management in conjunction with benzodiazepines, while an underlying cause is investigated. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Withdrawal seizures'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      While",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      may have a role in the outpatient management of mild alcohol withdrawal, convincing evidence that the drug effectively treats patients with delirium tremens or other severe symptoms is lacking [",
"      <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=see_link\">",
"       \"Ambulatory alcohol detoxification\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Centrally acting alpha-2 agonists and beta blockers &ndash; These agents may reduce minor symptoms of withdrawal, but they have not been shown to prevent the development of seizures or DT. We believe they should",
"      <strong>",
"       not",
"      </strong>",
"      be used for the treatment of acute severe alcohol withdrawal.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"       Baclofen",
"      </a>",
"      &ndash; Baclofen, a selective agonist of the gamma-aminobutyric acid (GABA)-B receptor used to treat reversible spasticity, has been studied as a therapy for acute alcohol withdrawal, but its effectiveness in controlling severe symptoms remains unproven [",
"      <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/53-56\">",
"       53-56",
"      </a>",
"      ]. We believe baclofen should",
"      <strong>",
"       not",
"      </strong>",
"      be used for the treatment of acute severe alcohol withdrawal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a history of seizures, delirium tremens, or prolonged, heavy alcohol consumption, who are minimally symptomatic or asymptomatic and are admitted to the hospital for other reasons, can be prophylactically treated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     chlordiazepoxide",
"    </a>",
"    . Should more severe symptoms develop, the patients are managed in standard fashion. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Management'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For prophylaxis, we give 50 to 100 mg every six hours for one day, followed by 25 to 50 mg every six hours for an additional two days. Monitoring is no different from patients in active withdrawal. Patients should be reassessed frequently and additional 25 to 50 mg doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     chlordiazepoxide",
"    </a>",
"    administered each hour if a score of 8 or greater is achieved on the Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWAS-Ar) (",
"    <a class=\"graphic graphic_table graphicRef64835 \" href=\"UTD.htm?20/61/21470\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20441/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Asymptomatic or minimally symptomatic patients at lower risk for seizures or delirium tremens who are being admitted to the hospital for other reasons should be closely monitored and may be treated with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"     chlordiazepoxide",
"    </a>",
"    25 to 50 mg every hour as needed when a score of 8 or greater is achieved on the CIWAS.",
"   </p>",
"   <p>",
"    After acute treatment, all patients should be screened for alcohol dependence and should be considered at risk for recurrent episodes of withdrawal. In-hospital evaluation and long-term follow-up are recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     ADDITIONAL RESOURCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional poison control centers in the United States are available at all times for consultation on patients who are critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    medical toxicologists available for bedside consultation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inpatient care. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?43/3/44081?source=see_link\">",
"       \"Patient information: Alcohol withdrawal (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A table summarizing the emergent management of alcohol withdrawal is provided (",
"    <a class=\"graphic graphic_table graphicRef64745 \" href=\"UTD.htm?15/18/15661\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alcohol withdrawal remains a clinical diagnosis. It may be necessary to perform extensive testing (eg, lumbar puncture and cranial CT) to rule out other diagnoses. Conditions such as infection, trauma, metabolic derangements, drug overdose, hepatic failure, and gastrointestinal bleeding can mimic or coexist with alcohol withdrawal. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Rule out alternative diagnoses'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alcohol withdrawal syndromes encompass symptoms ranging from mild tremulousness to life-threatening delirium tremens. A table summarizing the timing of withdrawal symptoms is provided (",
"      <a class=\"graphic graphic_table graphicRef75499 \" href=\"UTD.htm?12/5/12379\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Minor withdrawal symptoms'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Withdrawal seizures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Alcoholic hallucinosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Delirium tremens (DT)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Delirium tremens (DT) is a syndrome characterized by agitation, disorientation, hallucinations, and autonomic instability (tachycardia, hypertension, hyperthermia, and diaphoresis) in the setting of acute reduction or abstinence from alcohol. DT is associated with a mortality rate of up to 5 percent, but the rate can be substantially higher if the condition goes untreated. Alcoholic hallucinosis and DT are distinct clinical entities. Patients at risk and those who fail to respond appropriately to initial doses of sedatives should be monitored closely and treated aggressively (",
"      <a class=\"graphic graphic_table graphicRef73377 \" href=\"UTD.htm?31/49/32539\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Delirium tremens (DT)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for delirium tremens include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A history of sustained drinking",
"     </li>",
"     <li>",
"      A history of previous DT",
"     </li>",
"     <li>",
"      Age greater than 30",
"     </li>",
"     <li>",
"      The presence of a concurrent illness",
"     </li>",
"     <li>",
"      The presence of significant alcohol withdrawal in the presence of an elevated ethanol level",
"     </li>",
"     <li>",
"      A longer period (more than two days) between the last drink and the onset of withdrawal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients in alcohol withdrawal require medical treatment and observation. We suggest that patients who present with signs and symptoms of moderate or severe alcohol withdrawal be treated with benzodiazepines (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We give",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      5 to 10 mg IV, repeated every 5 to 10 minutes until symptoms are controlled.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       Lorazepam",
"      </a>",
"      may also be used (2 to 4 mg IV, repeated every 15 to 20 minutes). The general goal of sedation is a calm but alert state. Patients at greater risk for adverse outcomes may need heavier sedation. IV benzodiazepines should be continued until it is clear that the patient is no longer delirious and at high risk for aspiration, and that absorption from the gut is reliable. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment of psychomotor agitation with benzodiazepines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that benzodiazepines be dosed and administered using a validated assessment tool, such as the Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar) (",
"      <a class=\"graphic graphic_table graphicRef64835 \" href=\"UTD.htm?20/61/21470\">",
"       table 3",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). This requires formally assessing patients at regular intervals. Evaluation intervals as frequent as every 10 to 15 minutes are appropriate for patients with severe symptoms; an interval of four to six hours is reasonable for stable patients with mild symptoms. For acute withdrawal, we give",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      5 to 10 mg IV for any score of 8 or greater on the CIWA-Ar. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Symptom-triggered therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with moderate or severe alcohol withdrawal need close monitoring, some in an intensive care setting (",
"      <a class=\"graphic graphic_table graphicRef73377 \" href=\"UTD.htm?31/49/32539\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Disposition and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For delirium tremens refractory to aggressive treatment with high-dose benzodiazepines, we suggest treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients receiving these agents require ICU admission and will likely require mechanical ventilation (",
"      <a class=\"graphic graphic_table graphicRef64745 \" href=\"UTD.htm?15/18/15661\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Refractory delirium tremens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic or minimally symptomatic patients at risk for alcohol withdrawal, but admitted to the hospital for other reasons, should be closely monitored and may be treated prophylactically with oral benzodiazepines. We use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/36/4679?source=see_link\">",
"       chlordiazepoxide",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/1\">",
"      Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med 2003; 348:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/2\">",
"      Saitz R, O'Malley SS. Pharmacotherapies for alcohol abuse. Withdrawal and treatment. Med Clin North Am 1997; 81:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/3\">",
"      ISBELL H, FRASER HF, WIKLER A, et al. An experimental study of the etiology of rum fits and delirium tremens. Q J Stud Alcohol 1955; 16:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/4\">",
"      Mihic SJ, Ye Q, Wick MJ, et al. Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. Nature 1997; 389:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/5\">",
"      Morrow AL, Suzdak PD, Karanian JW, Paul SM. Chronic ethanol administration alters gamma-aminobutyric acid, pentobarbital and ethanol-mediated 36Cl- uptake in cerebral cortical synaptoneurosomes. J Pharmacol Exp Ther 1988; 246:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/6\">",
"      Hoffman PL, Grant KA, Snell LD, et al. NMDA receptors: role in ethanol withdrawal seizures. Ann N Y Acad Sci 1992; 654:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/7\">",
"      Tsai G, Gastfriend DR, Coyle JT. The glutamatergic basis of human alcoholism. Am J Psychiatry 1995; 152:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/8\">",
"      Etherington JM. Emergency management of acute alcohol problems. Part 1: Uncomplicated withdrawal. Can Fam Physician 1996; 42:2186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/9\">",
"      Victor M, Brausch C. The role of abstinence in the genesis of alcoholic epilepsy. Epilepsia 1967; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/10\">",
"      Alldredge BK, Lowenstein DH, Simon RP. Placebo-controlled trial of intravenous diphenylhydantoin for short-term treatment of alcohol withdrawal seizures. Am J Med 1989; 87:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/11\">",
"      Chance JF. Emergency department treatment of alcohol withdrawal seizures with phenytoin. Ann Emerg Med 1991; 20:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/12\">",
"      Rathlev NK, D'Onofrio G, Fish SS, et al. The lack of efficacy of phenytoin in the prevention of recurrent alcohol-related seizures. Ann Emerg Med 1994; 23:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/13\">",
"      VICTOR M, ADAMS RD. The effect of alcohol on the nervous system. Res Publ Assoc Res Nerv Ment Dis 1953; 32:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/14\">",
"      Abraham E, Shoemaker WC, McCartney SF. Cardiorespiratory patterns in severe delirium tremens. Arch Intern Med 1985; 145:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/15\">",
"      Berglund M, Risberg J. Regional cerebral blood flow during alcohol withdrawal related to consumption and clinical symptomatology. Acta Neurol Scand Suppl 1977; 64:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/16\">",
"      Elisaf M, Liberopoulos E, Bairaktari E, Siamopoulos K. Hypokalaemia in alcoholic patients. Drug Alcohol Rev 2002; 21:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/17\">",
"      Wadstein J, Skude G. Does hypokalaemia precede delirium tremens? Lancet 1978; 2:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/18\">",
"      Victor M. The role of hypomagnesemia and respiratory alkalosis in the genesis of alcohol-withdrawal symptoms. Ann N Y Acad Sci 1973; 215:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/19\">",
"      Ferguson JA, Suelzer CJ, Eckert GJ, et al. Risk factors for delirium tremens development. J Gen Intern Med 1996; 11:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/20\">",
"      Cushman P Jr. Delirium tremens. Update on an old disorder. Postgrad Med 1987; 82:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/21\">",
"      Schuckit MA, Tipp JE, Reich T, et al. The histories of withdrawal convulsions and delirium tremens in 1648 alcohol dependent subjects. Addiction 1995; 90:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/22\">",
"      Turner RC, Lichstein PR, Peden JG Jr, et al. Alcohol withdrawal syndromes: a review of pathophysiology, clinical presentation, and treatment. J Gen Intern Med 1989; 4:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/23\">",
"      DeBellis R, Smith BS, Choi S, Malloy M. Management of delirium tremens. J Intensive Care Med 2005; 20:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/24\">",
"      Pristach CA, Smith CM, Whitney RB. Alcohol withdrawal syndromes - prediction from detailed medical and drinking histories. Drug Alcohol Depend 1983; 11:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/25\">",
"      Boston, LN. Alcohol withdrawal. Lancet 1908; 1:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/26\">",
"      Yost DA. Alcohol withdrawal syndrome. Am Fam Physician 1996; 54:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/27\">",
"      TAVEL ME, DAVIDSON W, BATTERTON TD. A critical analysis of mortality associated with delirium tremens. Review of 39 fatalities in a 9-year period. Am J Med Sci 1961; 242:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/28\">",
"      Mayo-Smith MF, Beecher LH, Fischer TL, et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med 2004; 164:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/29\">",
"      Hecksel KA, Bostwick JM, Jaeger TM, Cha SS. Inappropriate use of symptom-triggered therapy for alcohol withdrawal in the general hospital. Mayo Clin Proc 2008; 83:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/30\">",
"      Hack JB, Hoffman RS. Thiamine before glucose to prevent Wernicke encephalopathy: examining the conventional wisdom. JAMA 1998; 279:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/31\">",
"      Hoffman RS, Goldfrank LR. The poisoned patient with altered consciousness. Controversies in the use of a 'coma cocktail'. JAMA 1995; 274:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/32\">",
"      Hoffman RS, Goldfrank LR. Ethanol-associated metabolic disorders. Emerg Med Clin North Am 1989; 7:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/33\">",
"      Kaim SC, Klett CJ, Rothfeld B. Treatment of the acute alcohol withdrawal state: a comparison of four drugs. Am J Psychiatry 1969; 125:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/34\">",
"      Holbrook AM, Crowther R, Lotter A, et al. Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. CMAJ 1999; 160:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/35\">",
"      Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 1997; 278:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/36\">",
"      Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev 2010; :CD005063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/37\">",
"      Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the Alcohol Withdrawal Syndrome. Cochrane Database Syst Rev 2011; :CD008537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/38\">",
"      Bird RD, Makela EH. Alcohol withdrawal: what is the benzodiazepine of choice? Ann Pharmacother 1994; 28:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/39\">",
"      Sullivan JT, Sykora K, Schneiderman J, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/40\">",
"      Spies CD, Otter HE, H&uuml;ske B, et al. Alcohol withdrawal severity is decreased by symptom-orientated adjusted bolus therapy in the ICU. Intensive Care Med 2003; 29:2230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/41\">",
"      Saitz R, Mayo-Smith MF, Roberts MS, et al. Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial. JAMA 1994; 272:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/42\">",
"      Jaeger TM, Lohr RH, Pankratz VS. Symptom-triggered therapy for alcohol withdrawal syndrome in medical inpatients. Mayo Clin Proc 2001; 76:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/43\">",
"      Daeppen JB, Gache P, Landry U, et al. Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med 2002; 162:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/44\">",
"      Cassidy EM, O'Sullivan I, Bradshaw P, et al. Symptom-triggered benzodiazepine therapy for alcohol withdrawal syndrome in the emergency department: a comparison with the standard fixed dose benzodiazepine regimen. Emerg Med J 2012; 29:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/45\">",
"      Cagetti E, Liang J, Spigelman I, Olsen RW. Withdrawal from chronic intermittent ethanol treatment changes subunit composition, reduces synaptic function, and decreases behavioral responses to positive allosteric modulators of GABAA receptors. Mol Pharmacol 2003; 63:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/46\">",
"      Nolop KB, Natow A. Unprecedented sedative requirements during delirium tremens. Crit Care Med 1985; 13:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/47\">",
"      Hack JB, Hoffmann RS, Nelson LS. Resistant alcohol withdrawal: does an unexpectedly large sedative requirement identify these patients early? J Med Toxicol 2006; 2:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/48\">",
"      McCowan C, Marik P. Refractory delirium tremens treated with propofol: a case series. Crit Care Med 2000; 28:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/49\">",
"      Coomes TR, Smith SW. Successful use of propofol in refractory delirium tremens. Ann Emerg Med 1997; 30:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/50\">",
"      Hodges B, Mazur JE. Intravenous ethanol for the treatment of alcohol withdrawal syndrome in critically ill patients. Pharmacotherapy 2004; 24:1578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/51\">",
"      Blum K, Eubanks JD, Wallace JE, Hamilton H. Enhancement of alcohol withdrawal convulsions in mice by haloperidol. Clin Toxicol 1976; 9:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/52\">",
"      Minozzi S, Amato L, Vecchi S, Davoli M. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev 2010; :CD005064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/53\">",
"      Colombo G, Serra S, Brunetti G, et al. Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend 2003; 70:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/54\">",
"      Addolorato G, Caputo F, Capristo E, et al. Rapid suppression of alcohol withdrawal syndrome by baclofen. Am J Med 2002; 112:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/55\">",
"      Addolorato G, Leggio L, Abenavoli L, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. Am J Med 2006; 119:276.e13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20441/abstract/56\">",
"      Liu J, Wang LN. Baclofen for alcohol withdrawal. Cochrane Database Syst Rev 2013; 2:CD008502.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 323 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-4F64B2DDF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_61_20441=[""].join("\n");
var outline_f19_61_20441=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Gamma-aminobutyric acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Excitatory amino acids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MINOR WITHDRAWAL SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      WITHDRAWAL SEIZURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ALCOHOLIC HALLUCINOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DELIRIUM TREMENS (DT)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clinical manifestations of severe withdrawal and DT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Rule out alternative diagnoses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Symptom control and supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment of psychomotor agitation with benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Drug selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Route",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Symptom-triggered therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Disposition and monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Refractory delirium tremens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Alternative and contraindicated agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      ADDITIONAL RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/323\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/323|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/4/24641\" title=\"algorithm 1\">",
"      Treatment of severe alcohol withdrawal without diazepam*",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/323|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/5/12379\" title=\"table 1\">",
"      Timing of withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/49/32539\" title=\"table 2\">",
"      ICU admission for withdrawal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/61/21470\" title=\"table 3\">",
"      CIWA-Ar withdrawal scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/18/15661\" title=\"table 4\">",
"      Moderate and severe alcohol withdrawal - Rapid overview",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?33/0/33796?source=related_link\" title=\"calculator 1\">",
"      Calculator: CIWA-Ar Clinical Institute Withdrawal Assessment for Alcohol scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4710?source=related_link\">",
"      Alcohol abuse and hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=related_link\">",
"      Ambulatory alcohol detoxification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/36/42569?source=related_link\">",
"      Approach to the patient with visual hallucinations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=related_link\">",
"      Brief intervention for unhealthy alcohol and other drug use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/42/21162?source=related_link\">",
"      Clinical manifestations and diagnosis of alcoholic fatty liver disease and alcoholic cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/2/9258?source=related_link\">",
"      Clinical manifestations and treatment of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2167?source=related_link\">",
"      Diagnosis and treatment of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39575?source=related_link\">",
"      Etiology and pathogenesis of chronic pancreatitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/32/13831?source=related_link\">",
"      Nutrition support in critically ill patients: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/24/40328?source=related_link\">",
"      Overview of the chronic neurologic complications of alcohol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?43/3/44081?source=related_link\">",
"      Patient information: Alcohol withdrawal (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/48/19209?source=related_link\">",
"      Pharmacotherapy for alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/62/10217?source=related_link\">",
"      Wernicke's encephalopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_61_20442="Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies";
var content_f19_61_20442=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/61/20442/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/61/20442/contributors\">",
"     Madhura Tamhankar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/61/20442/contributors\">",
"     Nicholas J Volpe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/61/20442/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/61/20442/contributors\">",
"     Paul W Brazis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?19/61/20442/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?19/61/20442/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?19/61/20442/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 14, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic optic neuropathy is the most common optic nerve disorder in patients over age 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/1\">",
"     1",
"    </a>",
"    ]. Ischemic optic neuropathy is generally categorized as anterior (affecting the optic disc) versus posterior (retrobulbar) and as arteritic versus nonarteritic. Anterior involvement is usual with both arteritic and nonarteritic ischemic optic neuropathy (AION and NAION).",
"   </p>",
"   <p>",
"    Nonarteritic anterior ischemic optic neuropathy (NAION) is the most common form of ischemic optic neuropathy. It is an idiopathic, ischemic insult of the optic nerve head characterized by acute, monocular, painless visual loss with optic disc swelling.",
"   </p>",
"   <p>",
"    This topic will discuss the epidemiology, pathogenesis, and causes of NAION. The clinical features, diagnosis, treatment, and prognosis of NAION are discussed separately. Other forms of ischemic optic neuropathy and other optic neuropathies are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27558?source=see_link\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9929?source=see_link\">",
"     \"Nonarteritic ischemic optic neuropathy: Prognosis and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4969?source=see_link\">",
"     \"Optic neuropathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VASCULAR ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optic nerve head (prelaminar and laminar portions) is supplied by 15 to 20 short posterior ciliary arteries that are derived from the ophthalmic artery and also by arterial branches from the anastomotic circle of Zinn-Haller [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. The circle of Zinn-Haller itself is fed by the short posterior ciliary arteries, branches of pial arterial network, and choroidal vessels (",
"    <a class=\"graphic graphic_figure graphicRef53007 \" href=\"UTD.htm?40/9/41110\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This vascular supply may demonstrate distinct upper and lower halves consistent with altitudinal damage to the optic nerve head [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27558?source=see_link\">",
"     \"Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The retina is supplied by the choroidal circulation and branches of the central retinal artery, both derived from the ophthalmic artery, a branch of the internal carotid artery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3882?source=see_link&amp;anchor=H2#H2\">",
"     \"Central and branch retinal artery occlusion\", section on 'Vascular anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;NAION is the most common optic neuropathy in middle aged and elderly patients, and constitutes 94 percent of all AION cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/6\">",
"     6",
"    </a>",
"    ]. The estimated annual incidence in the United States is 0.54 per 100,000 for all ages and 2.3 to 10.2 per every 100,000 persons older than 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. There are approximately 6000 new cases annually.",
"   </p>",
"   <p>",
"    NAION primarily occurs in older adults. The Ischemic Optic Neuropathy Decompression Trial (IONDT), a large prospective study population with age-defined entry criteria, reported a mean age of 66 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/7\">",
"     7",
"    </a>",
"    ]. Other population-based studies report a mean age of 61 to 72 years [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. NAION is considered unusual in patients under 45 years of age. However, in one case series of patients evaluated at a subspecialty clinic, 23 percent of individuals were less than 50 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caucasian individuals appear to be at higher risk than other ethnic groups [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. NAION affects both sexes equally [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/7,8,12\">",
"     7,8,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;NAION is believed to result from acute ischemia to the optic nerve head. However, the precise mechanism leading to optic disc ischemia is unclear. There has been histopathologic documentation of infarction, but not vasculopathy in NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/5,13,14\">",
"     5,13,14",
"    </a>",
"    ]. Because retinal or cerebral emboli are rarely detected in the setting of NAION, embolism from cardiac or larger artery disease is believed to underlie few, if any, NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. In contrast to retinal ischemia, NAION is not associated with carotid occlusive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of its strong association with age, diabetes, hypertension, and the known vascular supply of the optic nerve head, small arterial occlusive disease has been proposed as a mechanism of NAION. A magnetic resonance imaging study of 13 patients with NAION demonstrated a higher burden of white matter ischemic lesions compared with controls matched for age, hypertension, and diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/17\">",
"     17",
"    </a>",
"    ]. However, a small artery vasculopathy affecting the optic nerve circulation has not been pathologically identified in NAION patients.",
"   </p>",
"   <p>",
"    One hypothesis is that NAION results from transient hypoperfusion of the posterior ciliary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/5\">",
"     5",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29108?source=see_link\">",
"     Fluorescein",
"    </a>",
"    angiography in acute NAION shows delayed arterial filling, a finding that is not observed in cases of optic disc edema due to other etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Blood flow to the optic nerve head is maintained by autoregulatory mechanisms that include autonomic input to the blood vessels and release of vasoactive substances such as endothelin (vasoconstrictor) and nitric oxide (vasodilator). Disturbance in autoregulatory mechanisms may be induced by arteriosclerosis, vasospasm, and antihypertensive medications. In this setting, a critical fall of perfusion pressure in the capillaries supplying the optic nerve head may be caused either by a marked fall in blood pressure, a rise in the eye pressure, or blockage or sudden, severe narrowing of the internal carotid artery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ophthalmic artery. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Etiology and risk factors'",
"    </a>",
"    below.) Vasospasm has also been speculated to play a role [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/5,20,21\">",
"     5,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another theory is that NAION results from a process similar to that of a compartment syndrome. Some argue that the histopathologic characteristics of the injury, which, in some cases, included cavernous degeneration with substantial compression of adjacent normal axons by the degenerated nerve tissue, most favor this pathogenic mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Patients with NAION are believed to have a premorbid abnormality of optic disc structure (ie, a small cup with crowded optic nerve fibers) that predisposes them to NAION (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Ocular risk factors'",
"    </a>",
"    below). The effects of structural crowding in the optic nerve head may lead to mechanical obstruction of axoplasmic flow causing axonal swelling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    secondary compression of the microcirculation due to axoplasmic stasis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/5\">",
"     5",
"    </a>",
"    ]. The fact that a recurrence of NAION is uncommon in the same eye may support this hypothesis as the atrophy that follows ischemic injury may relieve nerve fiber crowding [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Others have proposed that occlusion of tributaries of the central retinal vein is the initial event in NAION, which leads to optic nerve head edema and secondary arteriolar constriction causing an ischemic infarction of the optic nerve [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/22\">",
"     22",
"    </a>",
"    ]. Purported risk factors such as sleep apnea and recumbent posture may cause an increase in venous pressure. Vasodilation of the central retinal artery causing a secondary obstruction of central retinal vein or its tributaries may also explain NAION occurring in association with prolonged hypotension, nocturnal hypotension, and use of phosphodiesterase-5 inhibitors.",
"   </p>",
"   <p>",
"    The most commonly proposed pathogenetic theory combines these mechanisms, proposing that insufficiency of the optic disc circulation, causes ischemia and swelling of the optic nerve, which in the setting of a crowded optic nerve head, leads to infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of NAION occur apparently spontaneously in the setting of one or more underlying atherosclerosis risk factors. In many case series and some case-control studies, several risk factors for NAION have been identified or suggested (",
"    <a class=\"graphic graphic_table graphicRef50757 \" href=\"UTD.htm?37/16/38155\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consistent with its presumed ischemic pathogenesis, atherosclerotic risk factors, smoking, hypertension, and diabetes have been associated with an increased risk of NAION; in the IONDT, one of these were present in 60 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/7\">",
"     7",
"    </a>",
"    ]. Overall, systemic hypertension has been reported in 34 to 49 percent of patients, while diabetes is seen in 5 to 28 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/7,10,11,23-25\">",
"     7,10,11,23-25",
"    </a>",
"    ]. NAION patients younger than 50 years old have a stronger association with diabetes, hypertension, and hypercholesterolemia than older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ischemic heart disease, hypercholesterolemia, stroke, tobacco use, and atherosclerosis have also been associated with NAION, but more variably [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/10,23-25,27-31\">",
"     10,23-25,27-31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Nocturnal hypotension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twenty-four hour ambulatory blood pressure recordings demonstrate a physiologic drop in systemic blood pressure during sleep that normalizes on awakening in the morning. Some evidence suggests that this nocturnal arterial hypotension may play a role in the development of NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Patients with NAION often discover vision loss upon awakening [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients with systemic hypertension and secondary impairment of autoregulation of the optic circulation may be particularly vulnerable to this putative complication of nocturnal hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/26,34\">",
"     26,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nocturnal blood pressure decreases may be exacerbated by antihypertensive medications, particularly when administered at night [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/36\">",
"     36",
"    </a>",
"    ]. Implicated medications include beta-blockers (oral agents and eyedrops), calcium-channel blockers, angiotensin converting enzyme inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"     terazosin",
"    </a>",
"    hydrochloride,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    , and other similar compounds [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/26,34,36,37\">",
"     26,34,36,37",
"    </a>",
"    ]. However, marked nocturnal hypotension has also been recorded in patients not taking such medications.",
"   </p>",
"   <p>",
"    One investigation found that patients with NAION had greater depressions in nocturnal blood pressure compared to controls, but this was not confirmed in another independent case series [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/26,38\">",
"     26,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prothrombotic risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of case reports have described NAION occurring in individuals with coagulation abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/39-44\">",
"     39-44",
"    </a>",
"    ]. However, systematic studies have not defined a clear association for all coagulation abnormalities. As an example, elevated homocysteine levels have been found in some case series of patients with NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/45-47\">",
"     45-47",
"    </a>",
"    ], but not in others [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One small case-control study of 25 patients with NAION found increased odds of activated protein C resistance and factor V Leiden mutation (OR 4.97; 95% CI:1.3 to 19.5) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/49\">",
"     49",
"    </a>",
"    ]. However, another case-control study of 61 patients with NAION did not find an association between the prothrombotic risk factors lupus anticoagulant, protein C or protein S, and antithrombin III, or prothrombotic polymorphisms in the genes for factor V, II, or methylenetetrahydrofolate reductase [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/25\">",
"     25",
"    </a>",
"    ]. In a follow-up investigation in this population, a significant association between a platelet polymorphism involving the glycoprotein Ib-alpha gene and NAION was identified [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/50\">",
"     50",
"    </a>",
"    ]. Patients carrying this allele were also more likely to have subsequent second eye involvement. It is speculated that this genetic change makes platelets more vulnerable to activation.",
"   </p>",
"   <p>",
"    The results of a comprehensive battery of coagulation studies were compared in a group of 35 patients with NAION who were younger than 65 years and 70 age, sex-matched healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/51\">",
"     51",
"    </a>",
"    ]. An abnormality was found in 51 percent of patients in 17 percent of controls. The most frequent abnormalities were an increased level of factor VIII and lipoprotein a. A family history of thromboembolism, age &le; 55 years, and absence of cardiovascular risk factors were predictors of a coagulation abnormality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ocular risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is believed that an important risk factor for NAION is a small optic nerve head with a small or absent physiologic cup. In one case series, this finding was noted in 82 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/11\">",
"     11",
"    </a>",
"    ]. Case-control studies have found a significantly smaller cup-to-disc ratio in the unaffected eye in patients with NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/25,52-56\">",
"     25,52-56",
"    </a>",
"    ]. Optic disc drusen is another disc anomaly that is believed to be associated with nerve fiber crowding and may predispose to NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/11,57\">",
"     11,57",
"    </a>",
"    ]. In contrast, the unaffected optic nerve head is normal-appearing in patients with arteritic anterior ischemic optic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The association between NAION and cataract surgery has been debated [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. A number of cases of NAION occurring in the first hours to weeks after surgery have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. One case series found that if NAION occurs after one cataract surgery, the risk in the other eye is as high as 30 to 50 percent after a subsequent surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/63\">",
"     63",
"    </a>",
"    ]. NAION has also been a reported complication following LASIK procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. It is suggested that a perioperative rise in intraocular pressure lead to decreased perfusion of the optic nerve head, but this is unproven.",
"   </p>",
"   <p>",
"    NAION is infrequently associated with other ocular conditions including acute angle closure glaucoma [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/66\">",
"     66",
"    </a>",
"    ], prolonged pressure on the eyeball from any cause, and marked optic disc edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sleep apnea syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association has been proposed between NAION and obstructive sleep apnea syndrome (SAS). One case control study found evidence of SAS on polysomnography in 71 percent of 17 patients with NAION versus 18 percent of 17 control patients referred for evaluation of possible restless legs syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/67\">",
"     67",
"    </a>",
"    ]. Another case series found that 89 percent of 27 consecutively diagnosed NAION patients had SAS on polysomnography, a prevalence almost five-times higher than expected based on other community-based studies [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. A screening questionnaire for SAS was employed in another case control study of 73 NAION patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/70\">",
"     70",
"    </a>",
"    ]. Cases were somewhat more likely than controls to report symptoms and characteristics consistent with SAS (OR 2.62; 95% CI: 1.03 to 6.6).",
"   </p>",
"   <p>",
"    SAS may increase the risk of NAION by several potential mechanisms: impaired optic nerve head blood flow autoregulation secondary to repeated apnea, optic nerve vascular dysregulation secondary to SAS-induced arterial blood flow variations, and direct optic nerve damage due to prolonged hypoxia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/67,71\">",
"     67,71",
"    </a>",
"    ]. One case series report of three patients with NAION and SAS suggests that treatment of SAS may not prevent NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/72\">",
"     72",
"    </a>",
"    ]. SAS may also be associated with increased intracranial hypertension and the pseudotumor cerebri syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15769?source=see_link&amp;anchor=H7#H7\">",
"     \"Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;NAION has been reported in patients with renal failure on peritoneal or hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/73-79\">",
"     73-79",
"    </a>",
"    ]. In contrast to other cases of NAION, children as young as 17 months are at risk [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/80-82\">",
"     80-82",
"    </a>",
"    ]. A bilateral, but not necessarily symmetric, presentation is common.",
"   </p>",
"   <p>",
"    Renal failure may contribute to the development of NAION via a number of mechanisms. The accelerated arteriosclerosis that occurs in patients with chronic renal failure may predispose patients to this complication. Most patients with NAION in this setting have either chronic hypotension or hypotensive episodes, usually related to dialysis. Anemia also appears to be a risk factor for NAION patients with renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/76\">",
"     76",
"    </a>",
"    ]. Some speculate that a rise in intraocular pressure during hemodialysis may contribute to NAION; however, the effects of dialysis on intraocular pressure are disputed [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Volume replacement, along with restoration of blood pressure during hemodialysis, is reported to improve visual function in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/74,76,84\">",
"     74,76,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uremia is also speculated to produce a toxic optic neuropathy, characterized by a more slowly progressive vision loss, with decreased pupillary response and papilledema and improvement with dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/84,85\">",
"     84,85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Perioperative ION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative ischemic optic neuropathy is a rare but potentially devastating complication of surgery and is the leading cause of postoperative blindness (other causes include retinal and cerebral ischemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/86-89\">",
"     86-89",
"    </a>",
"    ]. In contrast to ischemic optic neuropathy occurring in other clinical settings, posterior rather than anterior ischemic optic neuropathy may be a more common postoperative complication, particularly in association with lumbar spine surgery and radical neck dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiopulmonary bypass (CABG) and spine surgeries are the procedures most often associated with NAION, but it has also been reported with many other surgeries, particularly bilateral radical neck dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/90-94\">",
"     90-94",
"    </a>",
"    ] and other chest, abdominal, neck, and orthopedic surgeries [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/95-98\">",
"     95-98",
"    </a>",
"    ]. The incidence of ischemic optic neuropathy after CABG is reported between 0.06 and 0.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/89,99-102\">",
"     89,99-102",
"    </a>",
"    ] and after spine surgery is between 0.03 to 0.11 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/3,88,89,103\">",
"     3,88,89,103",
"    </a>",
"    ]. With other surgeries, it is a much less frequent complication, estimated at 0.0008 percent at one institution [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/104\">",
"     104",
"    </a>",
"    ]. NAION may also occur after cataract and other eye surgeries (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Ocular risk factors'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Perioperative NAION usually presents with vision loss in the immediate postoperative period, after recovery from general anesthesia. Compared with other causes of NAION, the visual deficit is usually profound and often (in 53 to 66 percent) bilateral [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/86,89,100,105\">",
"     86,89,100,105",
"    </a>",
"    ]. Because the erythrocyte sedimentation rate (ESR) and C-reactive protein can be elevated postoperatively in normal patients, these tests are not reliable in this setting to distinguish between arteritic ischemic optic neuropathy and NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. However, in the absence of presurgical symptoms that suggest giant cell arteritis, arteritic ischemic optic neuropathy in the postoperative setting is considered unlikely.",
"   </p>",
"   <p>",
"    Risk factors for perioperative ischemic optic neuropathy include [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/86,87,89,90,95,97,99-103,105,106,108\">",
"     86,87,89,90,95,97,99-103,105,106,108",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe prolonged arterial hypotension",
"     </li>",
"     <li>",
"      Hemodilution",
"     </li>",
"     <li>",
"      Use of vasoconstricting agents, pressor support",
"     </li>",
"     <li>",
"      Elevated pressor support",
"     </li>",
"     <li>",
"      Anemia",
"     </li>",
"     <li>",
"      Substantial blood loss, transfusion requirement",
"     </li>",
"     <li>",
"      Longer operation time",
"     </li>",
"     <li>",
"      Atherosclerotic risk factors",
"     </li>",
"     <li>",
"      Small optic cup, optic nerve crowding",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Use of the head down or prone position used in some spinal surgeries may also increase orbital venous pressure and is suggested to be a risk factor for ischemic optic neuropathy in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/86-88,103,109,110\">",
"     86-88,103,109,110",
"    </a>",
"    ]. Alternatively, direct ocular compression from the headrest can occur in prone position and has been implicated as a cause of optic nerve head ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/87,110,111\">",
"     87,110,111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients undergoing radical neck dissection, increased orbital venous pressure may result from internal jugular vein ligation and lead to decreased arterial perfusion pressure at the optic nerve head [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/90,91,112\">",
"     90,91,112",
"    </a>",
"    ]. Avoidance of simultaneous internal jugular vein ligation has been suggested to prevent this complication after radical neck dissection; however, staging the neck dissection does not appear to afford protection [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/90,92\">",
"     90,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Efforts to rapidly correct hemodynamic derangements are recommended and may mitigate the severity of permanent vision loss, but there are no controlled observations to corroborate this as a treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Similarly, avoidance of perioperative anemia with early transfusion has been suggested to prevent perioperative NAION, but a critical threshold of anemia or hypotension has not been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/87,103,105\">",
"     87,103,105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Phosphodiesterase-5 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phosphodiesterase-5 (PDE-5) inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    are generally prescribed to treat male sexual dysfunction. Several reports link these drugs with NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/113-118\">",
"     113-118",
"    </a>",
"    ]. An association is not proven, and patients with sexual dysfunction often have vascular risk factors that are also associated with NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/113,119\">",
"     113,119",
"    </a>",
"    ]. As an exception, one case report describes NAION occurring in a child prescribed sildenafil for pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A causal relationship is suggested by the close temporal proximity of drug administration and symptom onset in many of these cases. One case report in particular is compelling in describing multiple episodes of transient visual field loss, each episode occurring after taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/121\">",
"     121",
"    </a>",
"    ]. After a fifth dose, the patient experienced persistent monocular vision loss with clinical findings consistent with NAION. Two other cases have been described in which sequential symptoms were associated with drug rechallenge [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/113,122\">",
"     113,122",
"    </a>",
"    ]. Another study examined visual fields in five healthy volunteers after taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ; one patient developed bilateral superior and inferonasal visual field depression [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/123\">",
"     123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism by which PDE-5 inhibitors might cause NAION is not known. Some studies, although not others, suggest that in normal adults, these agents cause retinal vasodilation and increased optic nerve perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/124-127\">",
"     124-127",
"    </a>",
"    ]. It is possible that in patients with microvascular disease and impaired autoregulation, these agents might cause a \"shunting\" of blood flow away from these vessels and induce ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/119\">",
"     119",
"    </a>",
"    ]. In one case-control study, PDE-5 inhibitors were a risk factor for NAION only in the setting of comorbid cardiovascular disease or hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/128\">",
"     128",
"    </a>",
"    ]. Another possible mechanism by which these drugs might be associated with NAION is their hypotensive effect, which when they are used in the evening hours, could exacerbate nocturnal hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/119\">",
"     119",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Nocturnal hypotension'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    While the relationship between these medications and NAION is unproven, the FDA has issued a warning regarding a possible association with NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/129\">",
"     129",
"    </a>",
"    ]. We suggest that patients with risk factors for NAION (eg, cardiovascular risk factors, sleep apnea, on antihypertensive drugs, history of prior NAION) be counselled against the use of these medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Interferon-Alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon-alpha is used in the treatment of chronic hepatitis, as well as certain malignancies. NAION has been reported as an uncommon complication of interferon-alpha treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/130-136\">",
"     130-136",
"    </a>",
"    ]. NAION in these case reports tends to be bilateral and sequential, and may recur after restarting the medication. Clinical course is variable, with some patients improving after discontinuation of therapy. Possible pathogenic mechanisms include interferon-induced systemic hypotension, an immune complex deposition within the optic disc circulation, or another cytokine-mediated inflammatory reaction of the blood vessels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Amiodarone",
"    </span>",
"    &nbsp;&mdash;&nbsp;An association between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    and NAION is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/137\">",
"     137",
"    </a>",
"    ]. Amiodarone has also been suggested to cause a toxic optic neuropathy, although this remains unproven as well. An optic neuropathy related to direct toxic effects of the drug is suspected in patients who have a more insidious onset of vision loss with slow progression and simultaneous bilateral involvement, features that are atypical of NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/137-139\">",
"     137-139",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4969?source=see_link&amp;anchor=H20#H20\">",
"     \"Optic neuropathies\", section on 'Drugs and toxins'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link&amp;anchor=H14#H14\">",
"     \"Major side effects of amiodarone\", section on 'Optic neuropathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Not all case series distinguish between patients with a clinical presentation that suggests NAION versus those that are more consistent with a toxic neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/140,141\">",
"     140,141",
"    </a>",
"    ]. Another source of confusion is that patients taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    frequently have ischemic cardiac disease and therefore share risk factors with NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/142\">",
"     142",
"    </a>",
"    ]. Hence the apparent relationship may rather represent confounding rather than causation. Because of the uncertainty surrounding the association, some suggest that for patients taking amiodarone who develop an optic neuropathy, the dose of amiodarone be lowered",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    discontinued if therapeutic alternatives exist [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/138-140\">",
"     138-140",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Sympathomimetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports of NAION have been reported in which the onset of symptoms appeared to be related to the use of amphetamine or other sympathomimetic agent [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/143-145\">",
"     143-145",
"    </a>",
"    ]. These agents are also associated with stroke and other cardiovascular complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical diagnosis of stroke subtypes\", section on 'Other risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Blood loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vision loss in the setting of acute blood loss is often bilateral, but can be asymmetric and even strictly unilateral. When NAION occurs in this setting, the most frequent sources of bleeding are gastrointestinal tract in men and the uterus in women [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/146-149\">",
"     146-149",
"    </a>",
"    ]. NAION has also been reported to be a complication of trauma requiring massive volume resuscitation [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/150,151\">",
"     150,151",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few case reports have documented NAION occurring in migraineurs during an episode of migraine [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/152,153\">",
"     152,153",
"    </a>",
"    ]. Vasospasm may underlie such cases [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Carotid dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ischemic optic neuropathy is a rare complication of carotid dissection, occurring in 3 to 4 percent of cases, always in the setting of other clinical signs and symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/154,155\">",
"     154,155",
"    </a>",
"    ]. In contrast to atherosclerotic carotid disease, which is not believed to be associated with NAION, carotid dissection can cause abrupt rather than slowly progressive carotid occlusion and loss of distal perfusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Families with a strong predisposition to NAION have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/117,156,157\">",
"     117,156,157",
"    </a>",
"    ]. These cases are somewhat atypical. A survey of 79 individuals with NAION revealed a family history of NAION in a first degree relative in four [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/158\">",
"     158",
"    </a>",
"    ]. Investigators have sought to associate the mitochondrial mutations associated with Leber's hereditary optic neuropathy (LHON) with NAION. None of the affected individuals among three families with NAION had one of the major LHON mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/156\">",
"     156",
"    </a>",
"    ]. These were also not observed in another investigation of 19 patients without known family history [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/159\">",
"     159",
"    </a>",
"    ]. However, in the latter study and in another family with NAION, intermediate or secondary LHON mutations were more common in NAION patients compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/157,159\">",
"     157,159",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Metabolic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;One study found elevated plasma homocysteine and lipoprotein(a) levels, as well as low vitamin B6 levels in 85 patients with new onset NAION compared to 107 healthy controls, suggesting that these factors may increase the risk for developing NAION [",
"    <a class=\"abstract\" href=\"UTD.htm?19/61/20442/abstract/160\">",
"     160",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonarteritic anterior ischemic optic neuropathy (NAION) is an idiopathic, ischemic insult of the optic nerve head and is the most common form of optic neuropathy in older adults.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Older Caucasian adults (greater than 45 to 50 years) are most at risk of NAION. Men and women are affected approximately equally. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NAION is believed to result from vascular insufficiency of the optic nerve head. While atherosclerotic risk factors are prevalent in these patients, an underlying vasculopathy involving the optic nerve circulation has not been defined. A possible alternative or contributory mechanism involves a compartment syndrome affecting the optic nerve head. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of NAION occur apparently spontaneously in older adults with vascular risk factors (diabetes, hypertension). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Atherosclerosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A small optic cup, implying optic nerve fiber crowding, is a common finding in the fellow eye in patients with NAION and is believed to place individuals at risk for NAION. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Ocular risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NAION has been described in other clinical settings that are believed to play a role in its onset in specific cases (",
"      <a class=\"graphic graphic_table graphicRef50757 \" href=\"UTD.htm?37/16/38155\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Etiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/1\">",
"      Rucker JC, Biousse V, Newman NJ. Ischemic optic neuropathies. Curr Opin Neurol 2004; 17:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/2\">",
"      Mackenzie PJ, Cioffi GA. Vascular anatomy of the optic nerve head. Can J Ophthalmol 2008; 43:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/3\">",
"      Baig MN, Lubow M, Immesoete P, et al. Vision loss after spine surgery: review of the literature and recommendations. Neurosurg Focus 2007; 23:E15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/4\">",
"      Hayreh SS. The 1994 Von Sallman Lecture. The optic nerve head circulation in health and disease. Exp Eye Res 1995; 61:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/5\">",
"      Arnold AC. Pathogenesis of nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 2003; 23:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/6\">",
"      Guyer DR, Miller NR, Auer CL, Fine SL. The risk of cerebrovascular and cardiovascular disease in patients with anterior ischemic optic neuropathy. Arch Ophthalmol 1985; 103:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/7\">",
"      Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch Ophthalmol 1996; 114:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/8\">",
"      Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol 1994; 14:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/9\">",
"      Hattenhauer MG, Leavitt JA, Hodge DO, et al. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1997; 123:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/10\">",
"      Hayreh SS, Zimmerman MB. Optic disc edema in non-arteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2007; 245:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/11\">",
"      Preechawat P, Bruce BB, Newman NJ, Biousse V. Anterior ischemic optic neuropathy in patients younger than 50 years. Am J Ophthalmol 2007; 144:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/12\">",
"      Hayreh SS. Anterior ischemic optic neuropathy. Arch Neurol 1981; 38:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/13\">",
"      Tesser RA, Niendorf ER, Levin LA. The morphology of an infarct in nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2003; 110:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/14\">",
"      Knox DL, Kerrison JB, Green WR. Histopathologic studies of ischemic optic neuropathy. Trans Am Ophthalmol Soc 2000; 98:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/15\">",
"      Fry CL, Carter JE, Kanter MC, et al. Anterior ischemic optic neuropathy is not associated with carotid artery atherosclerosis. Stroke 1993; 24:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/16\">",
"      M&uuml;ller M, Kessler C, Wessel K, et al. Low-tension glaucoma: a comparative study with retinal ischemic syndromes and anterior ischemic optic neuropathy. Ophthalmic Surg 1993; 24:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/17\">",
"      Arnold AC, Hepler RS, Hamilton DR, Lufkin RB. Magnetic resonance imaging of the brain in nonarteritic ischemic optic neuropathy. J Neuroophthalmol 1995; 15:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/18\">",
"      Arnold AC, Hepler RS. Fluorescein angiography in acute nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1994; 117:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/19\">",
"      Arnold AC, Badr MA, Hepler RS. Fluorescein angiography in nonischemic optic disc edema. Arch Ophthalmol 1996; 114:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/20\">",
"      Hayreh SS, Piegors DJ, Heistad DD. Serotonin-induced constriction of ocular arteries in atherosclerotic monkeys. Implications for ischemic disorders of the retina and optic nerve head. Arch Ophthalmol 1997; 115:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/21\">",
"      Kaiser, HJ, Flammer, J, Messerli, J. Vasospasm: a risk factor for nonarteritic anterior ischemic optic neuropathy?. Neuro-ophthalmology 1996; 16:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/22\">",
"      Levin LA, Danesh-Meyer HV. Hypothesis: a venous etiology for nonarteritic anterior ischemic optic neuropathy. Arch Ophthalmol 2008; 126:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/23\">",
"      Jacobson DM, Vierkant RA, Belongia EA. Nonarteritic anterior ischemic optic neuropathy. A case-control study of potential risk factors. Arch Ophthalmol 1997; 115:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/24\">",
"      Hayreh SS, Joos KM, Podhajsky PA, Long CR. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1994; 118:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/25\">",
"      Salomon O, Huna-Baron R, Kurtz S, et al. Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy. Ophthalmology 1999; 106:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/26\">",
"      Hayreh SS, Zimmerman MB, Podhajsky P, Alward WL. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. Am J Ophthalmol 1994; 117:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/27\">",
"      Chung SM, Gay CA, McCrary JA 3rd. Nonarteritic ischemic optic neuropathy. The impact of tobacco use. Ophthalmology 1994; 101:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/28\">",
"      Deramo VA, Sergott RC, Augsburger JJ, et al. Ischemic optic neuropathy as the first manifestation of elevated cholesterol levels in young patients. Ophthalmology 2003; 110:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/29\">",
"      Giuffre, G. Hematologic risk factors for anterior ischemic optic neuropathy. Neuro-ophthalmology 1990; 10:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/30\">",
"      Talks SJ, Chong NH, Gibson JM, Dodson PM. Fibrinogen, cholesterol and smoking as risk factors for non-arteritic anterior ischaemic optic neuropathy. Eye (Lond) 1995; 9 ( Pt 1):85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/31\">",
"      Hayreh SS, Jonas JB, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy and tobacco smoking. Ophthalmology 2007; 114:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/32\">",
"      Hayreh SS. Duke-elder lecture. Systemic arterial blood pressure and the eye. Eye (Lond) 1996; 10 ( Pt 1):5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/33\">",
"      Hayreh, SS. Acute ischemic disorders of the optic nerve: Pathogenesis, Clinical Manifestations and Management. Ophthalmol Clin North Am 1996; 9:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/34\">",
"      Hayreh SS. Role of nocturnal arterial hypotension in the development of ocular manifestations of systemic arterial hypertension. Curr Opin Ophthalmol 1999; 10:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/35\">",
"      Hayreh SS, Podhajsky PA, Zimmerman B. Nonarteritic anterior ischemic optic neuropathy: time of onset of visual loss. Am J Ophthalmol 1997; 124:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/36\">",
"      Hayreh SS, Podhajsky P, Zimmerman MB. Role of nocturnal arterial hypotension in optic nerve head ischemic disorders. Ophthalmologica 1999; 213:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/37\">",
"      Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol 1999; 128:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/38\">",
"      Landau K, Winterkorn JM, Mailloux LU, et al. 24-hour blood pressure monitoring in patients with anterior ischemic optic neuropathy. Arch Ophthalmol 1996; 114:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/39\">",
"      Biousse V. Coagulation abnormalities and their neuro-ophthalmologic manifestations. Curr Opin Ophthalmol 1999; 10:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/40\">",
"      Acheson JF, Sanders MD. Coagulation abnormalities in ischaemic optic neuropathy. Eye (Lond) 1994; 8 ( Pt 1):89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/41\">",
"      Worrall BB, Moazami G, Odel JG, Behrens MM. Anterior ischemic optic neuropathy and activated protein C resistance. A case report and review of the literature. J Neuroophthalmol 1997; 17:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/42\">",
"      Srinivasan S, Fern A, Watson WH, McColl MD. Reversal of nonarteritic anterior ischemic optic neuropathy associated with coexisting primary antiphospholipid syndrome and Factor V Leiden mutation. Am J Ophthalmol 2001; 131:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/43\">",
"      Sinnreich M, Rossillion B, Landis T, et al. Bilateral optic ischemic neuropathy related to chronic hepatitis C-associated anticardiolipin antibodies. Eur Neurol 2003; 49:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/44\">",
"      Papageorgiou E, Karamagkiolis S, Dimera V. Nonarteritic anterior ischemic optic neuropathy and double thrombophilic defect: a new observation. Case Rep Ophthalmol 2012; 3:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/45\">",
"      Weger M, Stanger O, Deutschmann H, et al. Hyperhomocyst(e)inaemia, but not MTHFR C677T mutation, as a risk factor for non-arteritic ischaemic optic neuropathy. Br J Ophthalmol 2001; 85:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/46\">",
"      Pianka P, Almog Y, Man O, et al. Hyperhomocystinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. Ophthalmology 2000; 107:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/47\">",
"      Kawasaki A, Purvin VA, Burgett RA. Hyperhomocysteinaemia in young patients with non-arteritic anterior ischaemic optic neuropathy. Br J Ophthalmol 1999; 83:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/48\">",
"      Biousse V, Kerrison JB, Newman NJ. Is non-arteritic anterior ischaemic optic neuropathy related to homocysteine? Br J Ophthalmol 2000; 84:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/49\">",
"      Nagy V, Facsko A, Takacs L, et al. Activated protein C resistance in anterior ischaemic optic neuropathy. Acta Ophthalmol Scand 2004; 82:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/50\">",
"      Salomon O, Rosenberg N, Steinberg DM, et al. Nonarteritic anterior ischemic optic neuropathy is associated with a specific platelet polymorphism located on the glycoprotein Ibalpha gene. Ophthalmology 2004; 111:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/51\">",
"      Kuhli-Hattenbach C, Scharrer I, L&uuml;chtenberg M, Hattenbach LO. Selective thrombophilia screening of patients with nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2009; 247:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/52\">",
"      Feit RH, Tomsak RL, Ellenberger C Jr. Structural factors in the pathogenesis of ischemic optic neuropathy. Am J Ophthalmol 1984; 98:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/53\">",
"      Beck RW, Savino PJ, Repka MX, et al. Optic disc structure in anterior ischemic optic neuropathy. Ophthalmology 1984; 91:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/54\">",
"      Doro S, Lessell S. Cup-disc ratio and ischemic optic neuropathy. Arch Ophthalmol 1985; 103:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/55\">",
"      Saito H, Tomidokoro A, Tomita G, et al. Optic disc and peripapillary morphology in unilateral nonarteritic anterior ischemic optic neuropathy and age- and refraction-matched normals. Ophthalmology 2008; 115:1585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/56\">",
"      Contreras I, Rebolleda G, Noval S, Mu&ntilde;oz-Negrete FJ. Optic disc evaluation by optical coherence tomography in nonarteritic anterior ischemic optic neuropathy. Invest Ophthalmol Vis Sci 2007; 48:4087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/57\">",
"      Purvin V, King R, Kawasaki A, Yee R. Anterior ischemic optic neuropathy in eyes with optic disc drusen. Arch Ophthalmol 2004; 122:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/58\">",
"      Jonas JB, Gusek GC, Naumann GO. Anterior ischemic optic neuropathy: nonarteritic form in small and giant cell arteritis in normal sized optic discs. Int Ophthalmol 1988; 12:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/59\">",
"      Lee MS, Rizzo JF 3rd, Lessell S. Neuro-ophthalmologic complications of cataract surgery. Semin Ophthalmol 2002; 17:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/60\">",
"      McCulley TJ, Lam BL, Feuer WJ. Incidence of nonarteritic anterior ischemic optic neuropathy associated with cataract extraction. Ophthalmology 2001; 108:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/61\">",
"      Hayreh SS. Anterior ischemic optic neuropathy. IV. Occurrence after cataract extraction. Arch Ophthalmol 1980; 98:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/62\">",
"      McCulley TJ, Lam BL, Feuer WJ. Nonarteritic anterior ischemic optic neuropathy and surgery of the anterior segment: temporal relationship analysis. Am J Ophthalmol 2003; 136:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/63\">",
"      Lam BL, Jabaly-Habib H, Al-Sheikh N, et al. Risk of non-arteritic anterior ischaemic optic neuropathy (NAION) after cataract extraction in the fellow eye of patients with prior unilateral NAION. Br J Ophthalmol 2007; 91:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/64\">",
"      Lee AG, Kohnen T, Ebner R, et al. Optic neuropathy associated with laser in situ keratomileusis. J Cataract Refract Surg 2000; 26:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/65\">",
"      Cameron BD, Saffra NA, Strominger MB. Laser in situ keratomileusis-induced optic neuropathy. Ophthalmology 2001; 108:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/66\">",
"      Slavin ML, Margulis M. Anterior ischemic optic neuropathy following acute angle-closure glaucoma. Arch Ophthalmol 2001; 119:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/67\">",
"      Mojon DS, Hedges TR 3rd, Ehrenberg B, et al. Association between sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy. Arch Ophthalmol 2002; 120:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/68\">",
"      Palombi K, Renard E, Levy P, et al. Non-arteritic anterior ischaemic optic neuropathy is nearly systematically associated with obstructive sleep apnoea. Br J Ophthalmol 2006; 90:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/69\">",
"      Young T, Shahar E, Nieto FJ, et al. Predictors of sleep-disordered breathing in community-dwelling adults: the Sleep Heart Health Study. Arch Intern Med 2002; 162:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/70\">",
"      Li J, McGwin G Jr, Vaphiades MS, Owsley C. Non-arteritic anterior ischaemic optic neuropathy and presumed sleep apnoea syndrome screened by the Sleep Apnea scale of the Sleep Disorders Questionnaire (SA-SDQ). Br J Ophthalmol 2007; 91:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/71\">",
"      Mojon DS, Mathis J, Zulauf M, et al. Optic neuropathy associated with sleep apnea syndrome. Ophthalmology 1998; 105:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/72\">",
"      Behbehani R, Mathews MK, Sergott RC, Savino PJ. Nonarteritic anterior ischemic optic neuropathy in patients with sleep apnea while being treated with continuous positive airway pressure. Am J Ophthalmol 2005; 139:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/73\">",
"      Servilla KS, Groggel GC. Anterior ischemic optic neuropathy as a complication of hemodialysis. Am J Kidney Dis 1986; 8:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/74\">",
"      Jackson TL, Farmer CK, Kingswood C, Vickers S. Hypotensive ischemic optic neuropathy and peritoneal dialysis. Am J Ophthalmol 1999; 128:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/75\">",
"      Michaelson C, Behrens M, Odel J. Bilateral anterior ischaemic optic neuropathy associated with optic disc drusen and systemic hypotension. Br J Ophthalmol 1989; 73:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/76\">",
"      Haider S, Astbury NJ, Hamilton DV. Optic neuropathy in uraemic patients on dialysis. Eye (Lond) 1993; 7 ( Pt 1):148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/77\">",
"      Korzets A, Marashek I, Schwartz A, et al. Ischemic optic neuropathy in dialyzed patients: a previously unrecognized manifestation of calcific uremic arteriolopathy. Am J Kidney Dis 2004; 44:e93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/78\">",
"      Basile C, Addabbo G, Montanaro A. Anterior ischemic optic neuropathy and dialysis: role of hypotension and anemia. J Nephrol 2001; 14:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/79\">",
"      Winkelmayer WC, Eigner M, Berger O, et al. Optic neuropathy in uremia: an interdisciplinary emergency. Am J Kidney Dis 2001; 37:E23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/80\">",
"      Kim JS, Deputy S, Vives MT, Aviles DH. Sudden blindness in a child with end-stage renal disease. Pediatr Nephrol 2004; 19:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/81\">",
"      Lapeyraque AL, Haddad E, Andr&eacute; JL, et al. Sudden blindness caused by anterior ischemic optic neuropathy in 5 children on continuous peritoneal dialysis. Am J Kidney Dis 2003; 42:E3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/82\">",
"      Chutorian AM, Winterkorn JM, Geffner M. Anterior ischemic optic neuropathy in children: case reports and review of the literature. Pediatr Neurol 2002; 26:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/83\">",
"      Levy J, Tovbin D, Lifshitz T, et al. Intraocular pressure during haemodialysis: a review. Eye (Lond) 2005; 19:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/84\">",
"      Knox DL, Hanneken AM, Hollows FC, et al. Uremic optic neuropathy. Arch Ophthalmol 1988; 106:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/85\">",
"      Korzets Z, Zeltzer E, Rathaus M, et al. Uremic optic neuropathy. A uremic manifestation mandating dialysis. Am J Nephrol 1998; 18:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/86\">",
"      Lee LA, Roth S, Posner KL, et al. The American Society of Anesthesiologists Postoperative Visual Loss Registry: analysis of 93 spine surgery cases with postoperative visual loss. Anesthesiology 2006; 105:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/87\">",
"      Myers MA, Hamilton SR, Bogosian AJ, et al. Visual loss as a complication of spine surgery. A review of 37 cases. Spine (Phila Pa 1976) 1997; 22:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/88\">",
"      Stevens WR, Glazer PA, Kelley SD, et al. Ophthalmic complications after spinal surgery. Spine (Phila Pa 1976) 1997; 22:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/89\">",
"      Newman NJ. Perioperative visual loss after nonocular surgeries. Am J Ophthalmol 2008; 145:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/90\">",
"      Worrell L, Rowe M, Petti G. Amaurosis: a complication of bilateral radical neck dissection. Am J Otolaryngol 2002; 23:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/91\">",
"      Balm AJ, Brown DH, De Vries WA, Snow GB. Blindness: a potential complication of bilateral neck dissection. J Laryngol Otol 1990; 104:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/92\">",
"      Marks SC, Jaques DA, Hirata RM, Saunders JR Jr. Blindness following bilateral radical neck dissection. Head Neck 1990; 12:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/93\">",
"      Wilson JF, Freeman SB, Breene DP. Anterior ischemic optic neuropathy causing blindness in the head and neck surgery patient. Arch Otolaryngol Head Neck Surg 1991; 117:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/94\">",
"      Su&aacute;rez-Fern&aacute;ndez MJ, Clariana-Mart&iacute;n A, Menc&iacute;a-Guti&eacute;rrez E, et al. Bilateral anterior ischemic optic neuropathy after bilateral neck dissection. Clin Ophthalmol 2010; 4:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/95\">",
"      Sadaba LM, Garcia-Layana A, Maldonado MJ, Berian JM. Bilateral ischemic optic neuropathy after transurethral prostatic resection: a case report. BMC Ophthalmol 2006; 6:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/96\">",
"      Gilbert ME, Savino PJ, Sergott RC. Anterior ischaemic optic neuropathy after rotator cuff surgery. Br J Ophthalmol 2006; 90:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/97\">",
"      Dunker S, Hsu HY, Sebag J, Sadun AA. Perioperative risk factors for posterior ischemic optic neuropathy. J Am Coll Surg 2002; 194:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/98\">",
"      Janicki PK, Pai R, Kelly Wright J, et al. Ischemic optic neuropathy after liver transplantation. Anesthesiology 2001; 94:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/99\">",
"      Kalyani SD, Miller NR, Dong LM, et al. Incidence of and risk factors for perioperative optic neuropathy after cardiac surgery. Ann Thorac Surg 2004; 78:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/100\">",
"      Nuttall GA, Garrity JA, Dearani JA, et al. Risk factors for ischemic optic neuropathy after cardiopulmonary bypass: a matched case/control study. Anesth Analg 2001; 93:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/101\">",
"      Shapira OM, Kimmel WA, Lindsey PS, Shahian DM. Anterior ischemic optic neuropathy after open heart operations. Ann Thorac Surg 1996; 61:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/102\">",
"      Sweeney PJ, Breuer AC, Selhorst JB, et al. Ischemic optic neuropathy: a complication of cardiopulmonary bypass surgery. Neurology 1982; 32:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/103\">",
"      Chang SH, Miller NR. The incidence of vision loss due to perioperative ischemic optic neuropathy associated with spine surgery: the Johns Hopkins Hospital Experience. Spine (Phila Pa 1976) 2005; 30:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/104\">",
"      Warner ME, Warner MA, Garrity JA, et al. The frequency of perioperative vision loss. Anesth Analg 2001; 93:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/105\">",
"      Buono LM, Foroozan R. Perioperative posterior ischemic optic neuropathy: review of the literature. Surv Ophthalmol 2005; 50:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/106\">",
"      Moster ML. Visual loss after coronary artery bypass surgery. Surv Ophthalmol 1998; 42:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/107\">",
"      Margheritini F, Camillieri G, Mancini L, Mariani PP. C-reactive protein and erythrocyte sedimentation rate changes following arthroscopically assisted anterior cruciate ligament reconstruction. Knee Surg Sports Traumatol Arthrosc 2001; 9:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/108\">",
"      Sha'aban RI, Asfour WM. Visual loss after coronary artery bypass surgery. Saudi Med J 2000; 21:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/109\">",
"      Dilger JA, Tetzlaff JE, Bell GR, et al. Ischaemic optic neuropathy after spinal fusion. Can J Anaesth 1998; 45:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/110\">",
"      Alexandrakis G, Lam BL. Bilateral posterior ischemic optic neuropathy after spinal surgery. Am J Ophthalmol 1999; 127:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/111\">",
"      Delattre O, Thoreux P, Liverneaux P, et al. Spinal surgery and ophthalmic complications: a French survey with review of 17 cases. J Spinal Disord Tech 2007; 20:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/112\">",
"      Strome SE, Hill JS, Burnstine MA, et al. Anterior ischemic optic neuropathy following neck dissection. Head Neck 1997; 19:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/113\">",
"      Pomeranz HD, Bhavsar AR. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases. J Neuroophthalmol 2005; 25:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/114\">",
"      Cunningham AV, Smith KH. Anterior ischemic optic neuropathy associated with viagra. J Neuroophthalmol 2001; 21:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/115\">",
"      Pomeranz HD, Smith KH, Hart WM Jr, Egan RA. Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2002; 109:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/116\">",
"      Tarantini A, Faraoni A, Menchini F, Lanzetta P. Bilateral simultaneous nonarteritic anterior ischemic optic neuropathy after ingestion of sildenafil for erectile dysfunction. Case Rep Med 2012; 2012:747658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/117\">",
"      Felekis T, Asproudis I, Katsanos K, Tsianos E. A case of nonarteritic anterior ischemic optic neuropathy of a male with family history of the disease after receiving sildenafil. Clin Ophthalmol 2011; 5:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/118\">",
"      Moschos MM, Margetis I. Bilateral simultaneous anterior ischemic optic neuropathy associated with sildenafil. Case Rep Ophthalmol 2011; 2:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/119\">",
"      Hayreh SS. Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy: is there a cause and effect relationship? J Neuroophthalmol 2005; 25:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/120\">",
"      Sivaswamy L, Vanstavern GP. Ischemic optic neuropathy in a child. Pediatr Neurol 2007; 37:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/121\">",
"      Bollinger K, Lee MS. Recurrent visual field defect and ischemic optic neuropathy associated with tadalafil rechallenge. Arch Ophthalmol 2005; 123:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/122\">",
"      Pepin S, Pitha-Rowe I. Stepwise decline in visual field after serial sildenafil use. J Neuroophthalmol 2008; 28:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/123\">",
"      McCulley TJ, Lam BL, Marmor MF, et al. Acute effects of sildenafil (viagra) on blue-on-yellow and white-on-white Humphrey perimetry. J Neuroophthalmol 2000; 20:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/124\">",
"      Sponsel WE, Paris G, Sandoval SS, et al. Sildenafil and ocular perfusion. N Engl J Med 2000; 342:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/125\">",
"      Grunwald JE, Siu KK, Jacob SS, Dupont J. Effect of sildenafil citrate (Viagra) on the ocular circulation. Am J Ophthalmol 2001; 131:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/126\">",
"      Grunwald JE, Metelitsina T, Grunwald L. Effect of sildenafil citrate (Viagra) on retinal blood vessel diameter. Am J Ophthalmol 2002; 133:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/127\">",
"      Pache M, Meyer P, Pr&uuml;nte C, et al. Sildenafil induces retinal vasodilatation in healthy subjects. Br J Ophthalmol 2002; 86:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/128\">",
"      McGwin G Jr, Vaphiades MS, Hall TA, Owsley C. Non-arteritic anterior ischaemic optic neuropathy and the treatment of erectile dysfunction. Br J Ophthalmol 2006; 90:154.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/cder/consumerinfo/viagra/vIAGRA.htm (Accessed on July 11, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/130\">",
"      Lohmann CP, Kroher G, Bogenrieder T, et al. Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma. Lancet 1999; 353:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/131\">",
"      Purvin VA. Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 1995; 113:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/132\">",
"      Vardizer Y, Linhart Y, Loewenstein A, et al. Interferon-alpha-associated bilateral simultaneous ischemic optic neuropathy. J Neuroophthalmol 2003; 23:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/133\">",
"      Chan JW. Bilateral non-arteritic ischemic optic neuropathy associated with pegylated interferon for chronic hepatitis C. Eye (Lond) 2007; 21:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/134\">",
"      Sene D, Touitou V, Bodaghi B, et al. Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. World J Gastroenterol 2007; 13:3137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/135\">",
"      Berg KT, Nelson B, Harrison AR, et al. Pegylated interferon alpha-associated optic neuropathy. J Neuroophthalmol 2010; 30:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/136\">",
"      Seddik H, Tamzaourte M, Rouibaa F, et al. Irreversible anterior ischemic optic neuropathy complicating interferon alpha and ribaverin therapy. Int J Hepatol 2011; 2011:814242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/137\">",
"      Chen D, Hedges TR. Amiodarone optic neuropathy--review. Semin Ophthalmol 2003; 18:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/138\">",
"      Murphy MA, Murphy JF. Amiodarone and optic neuropathy: the heart of the matter. J Neuroophthalmol 2005; 25:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/139\">",
"      Macaluso DC, Shults WT, Fraunfelder FT. Features of amiodarone-induced optic neuropathy. Am J Ophthalmol 1999; 127:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/140\">",
"      Purvin V, Kawasaki A, Borruat FX. Optic neuropathy in patients using amiodarone. Arch Ophthalmol 2006; 124:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/141\">",
"      M&auml;ntyj&auml;rvi M, Tuppurainen K, Ik&auml;heimo K. Ocular side effects of amiodarone. Surv Ophthalmol 1998; 42:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/142\">",
"      Nagra PK, Foroozan R, Savino PJ, et al. Amiodarone induced optic neuropathy. Br J Ophthalmol 2003; 87:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/143\">",
"      Fivgas GD, Newman NJ. Anterior ischemic optic neuropathy following the use of a nasal decongestant. Am J Ophthalmol 1999; 127:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/144\">",
"      Chan JW. Acute nonarteritic ischaemic optic neuropathy after phentermine. Eye (Lond) 2005; 19:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/145\">",
"      Wijaya J, Salu P, Leblanc A, Bervoets S. Acute unilateral visual loss due to a single intranasal methamphetamine abuse. Bull Soc Belge Ophtalmol 1999; 271:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/146\">",
"      Johnson MW, Kincaid MC, Trobe JD. Bilateral retrobulbar optic nerve infarctions after blood loss and hypotension. A clinicopathologic case study. Ophthalmology 1987; 94:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/147\">",
"      Hayreh SS. Anterior ischemic optic neuropathy. VIII. Clinical features and pathogenesis of post-hemorrhagic amaurosis. Ophthalmology 1987; 94:1488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/148\">",
"      Ballen PH, Fox MJ, Weissman GS. Ischemic optic neuropathy secondary to intestinal hemorrhage. Ann Ophthalmol 1985; 17:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/149\">",
"      Foroozan R, Buono LM, Savino PJ. Optic disc structure and shock-induced anterior ischemic optic neuropathy. Ophthalmology 2003; 110:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/150\">",
"      Cullinane DC, Jenkins JM, Reddy S, et al. Anterior ischemic optic neuropathy: a complication after systemic inflammatory response syndrome. J Trauma 2000; 48:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/151\">",
"      Shaked G, Gavriel A, Roy-Shapira A. Anterior ischemic optic neuropathy after hemorrhagic shock. J Trauma 1998; 44:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/152\">",
"      Weinstein JM, Feman SS. Ischemic optic neuropathy in migraine. Arch Ophthalmol 1982; 100:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/153\">",
"      Katz B. Bilateral sequential migrainous ischemic optic neuropathy. Am J Ophthalmol 1985; 99:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/154\">",
"      Biousse V, Schaison M, Touboul PJ, et al. Ischemic optic neuropathy associated with internal carotid artery dissection. Arch Neurol 1998; 55:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/155\">",
"      Baumgartner RW, Bogousslavsky J. Clinical manifestations of carotid dissection. Front Neurol Neurosci 2005; 20:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/156\">",
"      Hayreh SS, Fingert JH, Stone E, Jacobson DM. Familial non-arteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2008; 246:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/157\">",
"      Fingert JH, Grassi MA, Janutka JC, et al. Mitochondrial variant G4132A is associated with familial non-arteritic anterior ischemic optic neuropathy in one large pedigree. Ophthalmic Genet 2007; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/158\">",
"      Wang MY, Sadun F, Levin LB, et al. Occurrence of familial nonarteritic anterior ischemic optic neuropathy in a case series. J Neuroophthalmol 1999; 19:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/159\">",
"      Bosley TM, Abu-Amero KK, Ozand PT. Mitochondrial DNA nucleotide changes in non-arteritic ischemic optic neuropathy. Neurology 2004; 63:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?19/61/20442/abstract/160\">",
"      Giambene B, Sodi A, Sofi F, et al. Evaluation of traditional and emerging cardiovascular risk factors in patients with non-arteritic anterior ischemic optic neuropathy: a case-control study. Graefes Arch Clin Exp Ophthalmol 2009; 247:693.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5233 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9F1D191359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_61_20442=[""].join("\n");
var outline_f19_61_20442=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VASCULAR ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Nocturnal hypotension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prothrombotic risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ocular risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sleep apnea syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Renal failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Perioperative ION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Phosphodiesterase-5 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Interferon-Alpha",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Amiodarone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Sympathomimetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Blood loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Migraine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Carotid dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Metabolic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5233\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5233|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/9/41110\" title=\"figure 1\">",
"      Vascular supply optic nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5233|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/16/38155\" title=\"table 1\">",
"      Causes of NAION",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3882?source=related_link\">",
"      Central and branch retinal artery occlusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15769?source=related_link\">",
"      Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/58/27558?source=related_link\">",
"      Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9929?source=related_link\">",
"      Nonarteritic ischemic optic neuropathy: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/54/4969?source=related_link\">",
"      Optic neuropathies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f19_61_20443="Normal GFR children";
var content_f19_61_20443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal glomerular filtration rate (GFR) in children and young adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age (gender)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean GFR &plusmn; SD mL/min/1.73m",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 week (males and females)",
"       </td>",
"       <td>",
"        40.6&plusmn;14.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2-8 weeks (males and females)",
"       </td>",
"       <td>",
"        65.8&plusmn;24.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;8 weeks (males and females)",
"       </td>",
"       <td>",
"        95.7&plusmn;21.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2-12 years (males and females)",
"       </td>",
"       <td>",
"        133.0&plusmn;27.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13-21 years (males)",
"       </td>",
"       <td>",
"        140.0&plusmn;30.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13-21 years&nbsp;(females)",
"       </td>",
"       <td>",
"        126.0&plusmn;22.0",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SD: standard deviation; SCr: serum creatinine in mg/dL.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease. Evaluation, classification and stratification. Am J Kidney Dis 2002:39(Suppl 1):S1-S266. Table 24 (page S56). Copyright &copy;2002 National Kidney Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_61_20443=[""].join("\n");
var outline_f19_61_20443=null;
var title_f19_61_20444="Hypotension guidelines";
var content_f19_61_20444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hypotension guidelines",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        The optimal minimum blood pressure for burn patient must be individualized. Some patients will maintain adequate organ perfusion (and thus have adequate UOP) at MAPs lower than 70. True hypotension must be correlated with UOP. If a MAP (generally &lt;55 mm Hg) is not adequate to maintain the UOP goal of at least 30 mL/h then the following steps are recommended.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Start with Vasopressin 0.04 units/min drip (DO NOT TITRATE).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Monitor CVP (goal 8-10).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. If CVP not at goal then increase fluid rate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. If CVP at goal then add Levophed (norepinephrine) 2-20 mcg/min.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5. If additional pressors are needed, consider the placement of a PA catheter to guide resuscitation with specific PCWP and SVO2 goals (goal PCWP 10-12, SVO2 65 percent-70 percent). These patients may be volume depleted but a missed injury should be suspected.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        a. If PCWP not at goal then increase fluid rate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        b. If PCWP at goal then consider Dobutamine 5 mcg/kg/min (titrate until SvO2 at goal). Max dose of Dobutamine is 20 mcg/kg/min.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        c. If hypotension persists, look for missed injury.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        d. Consider adding epinephrine or neosynephrine as a last resort.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        6. If the patient is exhibiting catecholamine-resistant shock, consider the following diagnoses.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        a. Missed injury and on-going blood loss.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        b. Acidemia. If pH &lt;7.20 then adjust ventilator settings to optimize ventilation (Target PCO2 30-35). If despite optimal ventilation, patient is still has a pH &lt;7.2, consider bicarb administration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        c. Adrenal insufficiency. Check a random cortisol and add start hydrocortisone 100 mg every 8 hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        d. Hypocalcemia. Maintain Ionized Calcium &gt;1.1.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Ennis JL, Chung KK, Renz EM, et al. Joint theater trauma system implementation of burn resuscitation guidelines improves outcomes in severely burned military casaualties. J Trauma 2008; 65:S146. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_61_20444=[""].join("\n");
var outline_f19_61_20444=null;
var title_f19_61_20445="Diagnostic yield of screening for X linked disorders in ID";
var content_f19_61_20445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51263&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Yield of screening for X linked disorders in individuals with intellectual disability",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Population tested",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic yield*",
"        <br/>",
"        (percent of patients with positive results)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Testing the whole X chromosome or testing multiple X-linked genes specifically:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Definitely X-linked",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         Testing the whole X chromosome or multiple X-linked ID genes specifically is recommended in male patients with a family history suggestive of X-linked inheritance of ID",
"        </p>",
"        <p>",
"         Mutations in X-linked genes account for 10 percent of all cases with ID",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Possibly X-linked",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Specific testing for fragile X (trinucleotide repeat expansion of the",
"        <em>",
"         FMR1",
"        </em>",
"        gene):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Males with clinical features of fragile X syndrome",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td rowspan=\"4\">",
"        Testing is suggested in children with the following characteristics:",
"        <sup>",
"         [1,2]",
"        </sup>",
"        <ul>",
"         <li>",
"          Male or female children with ID and clinical features suggestive of fragile X syndrome, such as macrocephaly, large ears, enlarged testes, perseverative speech, lack of eye contact",
"         </li>",
"         <li>",
"          Male or female children with ID and a family history of ID",
"         </li>",
"         <li>",
"          Children with unexplained ID whose first-line CMA testing is normal (or benign)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Males with unexplained GDD/ID",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Males or females with mild to moderate unexplained GDD/ID",
"       </td>",
"       <td>",
"        2-3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Females with unexplained GDD/ID",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Specific testing for Rett syndrome (",
"        <em>",
"         MeCP2",
"        </em>",
"        testing)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Females with moderate to severe GDD/ID",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td rowspan=\"2\">",
"        Recommended in patients with the following:",
"        <ul>",
"         <li>",
"          Girls with severe ID",
"         </li>",
"         <li>",
"          Girls with clinical features of Rett syndrome",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Males with moderate to severe GDD/ID",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Specific testing for",
"        <em>",
"         JARID1C:",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unrelated males",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Specific testing for",
"        <em>",
"         ARX:",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Possibly X-linked",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Specific testing for",
"        <em>",
"         SLC6A8:",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Unrelated males",
"       </td>",
"       <td>",
"        &lt;1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GDD: global developmental delay; ID: intellectual disability; CMA: chromosomal microarray analysis (also known as comparative genomic hybridization).",
"     <br>",
"      * Represents approximate diagnostic yield, based on a meta-analysis of population studies. Most of the included studies were \"class III\" defined as a sample of patients studied during the course of a condition, rather than a population-based sample.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Hagerman RJ, Amiri K, Cronister A. Fragile X chechlist. Am J Med Genet 1991; 38:283.",
"       </li>",
"       <li>",
"        Miller DT, Adam MP, Aradhya S, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet 2010; 86:749.",
"       </li>",
"      </ol>",
"      Data from: Michelson DJ, Shevell MI, Sherr EH, Moeschler JB, Gropman AL, Ashwal S. Evidence report: Genetic and metabolic testing on children with global developmental delay. Neurology 2011; 77:1629.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_61_20445=[""].join("\n");
var outline_f19_61_20445=null;
var title_f19_61_20446="Countercurrent mechanism I";
var content_f19_61_20446=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56829&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Role of active NaCl transport in initiating contercurrent multiplication",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 187px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In step 1, at time zero, the fluid in the descending and ascending limbs and the interstitium is isomotic to plasma. In step 2, NaCl is transported out of the ascending limb into the interstitium to a gradient of 200 mosmol/kg. In step 3, the fluid in the descending limb equilibrates osmotically with the hypersmotic interstitium, primarily by water movement out of the tubule. Dilution of the interstitium by this water movement out of the tubule. Dilution of the interstitium by this water movement is prevented by continued NaCl transport out of the ascending limb. The result is the creation of an osmotic gradient between the ascending limb and the relatively hypersmotic descending limb and interstitium.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_61_20446=[""].join("\n");
var outline_f19_61_20446=null;
var title_f19_61_20447="CHD mortality related to BP and age";
var content_f19_61_20447=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    CHD mortality related to blood pressure and age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 398px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronary heart disease (CHD) mortality rate, pictured on a log scale with 95 percent confidence intervals, in each decade of age in relation to the estimated usual systolic and diastolic blood pressure at the start of that decade. CHD mortality increases with both higher pressures and older ages. For diastolic pressure, each age-specific regression line ignores the left-hand point (ie, at slightly less than 75 mmHg) for which the risk lies significantly above the fitted regression line (as indicated by the broken line below 75 mmHg).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Prospective Studies Collaboration, Lancet 2002; 360:1903.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f19_61_20447=[""].join("\n");
var outline_f19_61_20447=null;
